Research Report Olfactory and respiratory lamina propria transplantation after spinal cord transection in rats : Effects on functional recovery and axonal regeneration Lígia Aline Centenaroa , b , Mariane da Cunha Jaegerb , Jocemar Ilhaa , b , Marcelo Alves de Souzac , Pedro Ivo Kalil-Gasparb , Núbia Broetto Cunhaa , b , Simone Marcuzzoa , b , Matilde Achavala , b , aPrograma de Pós-Graduação em Neurociências , Instituto de Ciências Básicas da Saúde , Universidade Federal do Rio Grande do Sul , Rua Sarmento Leite 500 , CEP : 90050-170 , Porto Alegre , RS , Brazil bLaboratório de Histofisiologia Comparada , Departamento de Ciências Morfológicas , Instituto de Ciências Básicas da Saúde , Universidade Federal do Rio Grande do Sul , Rua Sarmento Leite 500 , CEP : 90050-170 , Porto Alegre , RS , Brazil cLaboratório de Neuroendocrinologia do Comportamento , Departamento de Fisiologia , Instituto de Ciências Básicas da Saúde , Universidade Federal do Rio Grande do Sul , Rua Sarmento Leite 500 , CEP : 90050-170 , Porto Alegre , RS , Brazil A B S T R A C T Spinal cord injury -LRB- SCI -RRB- has very poor clinical prospects , resulting in irreversible loss of function below the injury site .	1
Research Report Olfactory	1
respiratory lamina propria transplantation after spinal cord transection in rats : Effects on functional recovery and axonal regeneration Lígia Aline Centenaroa , b , Mariane da Cunha Jaegerb , Jocemar Ilhaa , b , Marcelo Alves de Souzac , Pedro Ivo Kalil-Gasparb , Núbia Broetto Cunhaa , b , Simone Marcuzzoa , b , Matilde Achavala , b , aPrograma de Pós-Graduação em Neurociências , Instituto de Ciências Básicas da Saúde	31
respiratory lamina propria transplantation	31
spinal cord transection in rats : Effects on functional recovery and axonal regeneration Lígia Aline Centenaroa , b , Mariane da Cunha Jaegerb , Jocemar Ilhaa , b , Marcelo Alves de Souzac , Pedro Ivo Kalil-Gasparb , Núbia Broetto Cunhaa , b , Simone Marcuzzoa , b , Matilde Achavala , b , aPrograma de Pós-Graduação em Neurociências , Instituto de Ciências Básicas da Saúde	80
spinal cord transection in rats	80
spinal cord transection	80
rats	107
Effects on functional recovery and axonal regeneration Lígia Aline Centenaroa , b , Mariane da Cunha Jaegerb , Jocemar Ilhaa , b , Marcelo Alves de Souzac , Pedro Ivo Kalil-Gasparb , Núbia Broetto Cunhaa , b , Simone Marcuzzoa , b , Matilde Achavala , b , aPrograma de Pós-Graduação em Neurociências , Instituto de Ciências Básicas da Saúde	113
Effects	113
functional recovery and axonal regeneration Lígia Aline Centenaroa , b , Mariane da Cunha Jaegerb , Jocemar Ilhaa , b , Marcelo Alves de Souzac , Pedro Ivo Kalil-Gasparb , Núbia Broetto Cunhaa , b , Simone Marcuzzoa , b , Matilde Achavala , b , aPrograma de Pós-Graduação em Neurociências , Instituto de Ciências Básicas da Saúde	124
axonal regeneration Lígia Aline Centenaroa , b , Mariane da Cunha Jaegerb , Jocemar Ilhaa , b , Marcelo Alves de Souzac , Pedro Ivo Kalil-Gasparb , Núbia Broetto Cunhaa , b , Simone Marcuzzoa , b , Matilde Achavala , b , aPrograma de Pós-Graduação em Neurociências , Instituto de Ciências	148
axonal regeneration Lígia Aline Centenaroa	148
b	194
Mariane da Cunha Jaegerb	197
Jocemar Ilhaa	223
b	238
Marcelo Alves de Souzac	241
Pedro Ivo Kalil-Gasparb	266
Núbia Broetto Cunhaa	291
b	313
Simone Marcuzzoa	316
b	334
Matilde Achavala	337
b	355
aPrograma de Pós-Graduação em Neurociências	359
aPrograma de Pós-Graduação	359
em Neurociências	386
Instituto de Ciências	404
Universidade Federal	444
Rio Grande	468
Sul	482
Rua Sarmento Leite 500	487
CEP	511
90050-170 , Porto Alegre	516
90050-170	516
Porto Alegre	527
RS	541
Brazil bLaboratório de Histofisiologia Comparada	545
Departamento de Ciências Morfológicas	595
Instituto de Ciências Básicas da Saúde	634
Instituto de Ciências Básicas	634
da Saúde	664
Universidade Federal	674
Rio Grande	698
Sul	712
Rua Sarmento Leite 500	717
CEP	741
90050-170 , Porto Alegre	746
90050-170	746
Porto Alegre	757
RS	771
Brazil cLaboratório de Neuroendocrinologia	775
Comportamento , Departamento de Fisiologia	821
Instituto de Ciências Básicas da Saúde	864
Instituto de Ciências Básicas	864
da Saúde	894
Universidade Federal	904
Rio Grande	928
Sul	942
Rua Sarmento Leite 500	947
CEP	971
90050-170 , Porto Alegre	976
90050-170	976
Porto Alegre	987
RS	1001
Brazil A B S T R A C T Spinal cord injury -LRB- SCI -RRB-	1005
Brazil A B S T R A C T Spinal cord injury	1005
SCI	1050
very poor clinical prospects	1059
irreversible loss of function	1102
irreversible loss	1102
function	1123
the injury site	1138
clinical trials	1175
olfactory ensheathing cells transplantation -LRB- OEC -RRB- derived from lamina propria -LRB- OLP -RRB-	1192
olfactory ensheathing cells transplantation -LRB- OEC -RRB- derived from lamina propria	1192
olfactory ensheathing cells transplantation -LRB- OEC -RRB-	1192
olfactory ensheathing cells transplantation	1192
OEC	1237
lamina propria	1255
OLP	1271
a controversial repair strategy	1285
The present study	1318
the efficacy of OLP or respiratory lamina propria -LRB- RLP -RRB- transplantation and the optimum period after SCI	1345
the efficacy	1345
OLP or respiratory lamina propria -LRB- RLP -RRB- transplantation and the optimum period after SCI	1361
OLP or respiratory lamina propria -LRB- RLP -RRB- transplantation	1361
OLP or respiratory lamina propria	1361
RLP	1396
transplantation	1401
the optimum period after SCI	1421
the optimum period	1421
SCI	1446
application of this potential therapy	1454
application	1454
this potential therapy	1469
Adult male rats	1493
spinal cord transection	1527
acute , 2-week or 4-week post-injury transplantation with pieces of OLP -LRB- containing OECs -RRB- or RLP -LRB- without OECs -RRB-	1565
acute , 2-week or 4-week post-injury transplantation with pieces of OLP -LRB- containing OECs -RRB-	1565
acute , 2-week or 4-week post-injury transplantation with pieces of OLP	1565
acute , 2-week or 4-week post-injury transplantation	1565
pieces of OLP	1622
pieces	1622
OLP	1632
OECs	1648
RLP -LRB- without OECs -RRB-	1657
RLP	1657
OECs	1670
animals with OLP and RLP	1693
animals	1693
OLP and RLP	1706
discrete and similar hindlimb motor	1725
improvement , with comparable spinal cord tissue sparing and sprouting in the lesion area	1761
improvement	1761
comparable spinal cord tissue sparing	1779
the lesion area	1834
Acute transplantation of OLP and RLP	1851
Acute transplantation	1851
OLP and RLP	1876
limited supraspinal axonal regeneration	1904
the presence of neurons stained by retrograde tracing in the brainstem nuclei	1956
the presence	1956
neurons stained by retrograde tracing in the brainstem nuclei	1972
neurons	1972
the brainstem nuclei	2013
A larger number of 5-HT positive fibers	2035
A larger number	2035
5-HT positive fibers	2054
the cranial stump of the OLP and RLP groups	2089
the cranial stump	2089
the OLP and RLP groups	2110
the lesion and caudal regions	2145
Calcitonin gene-related peptide fibers	2176
considerable numbers at the SCI site	2231
considerable numbers	2231
the SCI site	2255
both types of transplantation	2271
both types	2271
transplantation	2285
Our results	2302
differences between acute , 2-week and 4-week delayed transplantation of OLP and RLP	2331
differences	2331
acute , 2-week and 4-week delayed transplantation of OLP and RLP	2351
acute , 2-week and 4-week delayed transplantation	2351
OLP and RLP	2403
the limited functional and axon reparative effects observed	2432
the limited functional and axon reparative effects	2432
OECs	2528
A greater understanding of the effects of these tissue grafts	2534
A greater understanding	2534
the effects of these tissue grafts	2561
the effects	2561
these tissue grafts	2576
the rationale	2623
application of this treatment in humans	2641
application	2641
this treatment in humans	2656
this treatment	2656
humans	2674
Introduction Spinal cord injury -LRB- SCI -RRB-	2686
Introduction Spinal cord injury	2686
Introduction	2686
Spinal cord injury	2699
SCI	2719
loss of central control ofmotor , sensorial , and autonomic functions	2735
loss	2735
central control ofmotor , sensorial , and autonomic functions	2743
central control ofmotor	2743
sensorial	2768
autonomic functions	2783
the site of injury -LRB- van den Berg et al. , 2010 -RRB-	2809
the site	2809
injury -LRB- van den Berg et al. , 2010 -RRB-	2821
injury	2821
van den Berg et al. , 2010	2829
van den Berg	2829
et al.	2842
2010	2850
the application of neuroprotective treatments , such as methylprednisolone or interleukin-10	2865
the application	2865
neuroprotective treatments	2884
methylprednisolone or interleukin-10	2920
the clinical prospects for spinal cord lesions	2958
the clinical prospects	2958
spinal cord lesions	2985
Fitch and Silver , 2008 ; Takami et al. , 2002b	3030
Fitch and Silver	3030
2008 ; Takami et al.	3048
2008	3048
Takami et al.	3054
Takami	3054
et al.	3061
2002b	3069
Functional disabilities	3077
local neuronal death and loss of ascending and descending axons in the spinal cord , either by direct trauma or secondary damage -LRB- Hausmann , 2003 ; Ramer et al. , 2005 -RRB-	3114
local neuronal death	3114
loss of ascending and descending axons in the spinal cord , either by direct trauma or secondary damage -LRB- Hausmann , 2003 ; Ramer et al. , 2005 -RRB-	3139
loss	3139
axons	3172
the spinal cord	3181
direct trauma or secondary damage -LRB- Hausmann , 2003 ; Ramer et al. , 2005 -RRB-	3208
direct trauma or secondary damage	3208
Hausmann , 2003 ; Ramer et al. , 2005	3243
Hausmann	3243
2003 ; Ramer et al.	3253
2003	3253
Ramer et al.	3259
Ramer	3259
et al.	3265
2005	3273
The hostile environment produced by glial scarring , the presence of inhibitory molecules associated with oligodendrocyte myelin and inadequate neurotrophin supply	3279
The hostile environment	3279
glial scarring , the presence of inhibitory molecules associated with oligodendrocyte myelin and inadequate neurotrophin supply	3315
glial scarring	3315
the presence of inhibitory molecules associated with oligodendrocyte myelin and inadequate neurotrophin supply	3331
the presence	3331
inhibitory molecules associated with oligodendrocyte myelin and inadequate neurotrophin supply	3347
inhibitory molecules	3347
oligodendrocyte myelin and inadequate neurotrophin supply	3384
oligodendrocyte	3384
impaired regeneration of severed axons after SCI -LRB- Franssen et al. , 2007 -RRB-	3462
impaired regeneration	3462
severed axons after SCI	3487
severed axons	3487
SCI	3507
Franssen	3512
et al. , 2007	3521
et al.	3521
2007	3529
attempts to provide a cellular milieu appropriate for axonal regrowth and the restoration of lost neural circuits	3539
a cellular milieu	3559
axonal regrowth and the restoration of lost neural circuits	3593
axonal regrowth	3593
the restoration of lost neural circuits	3613
the restoration	3613
lost neural circuits	3632
several primary cell types	3654
transplantations	3699
the SCI site -LRB- Kwon and Tetzlaff , 2001 ; Tetzlaff et al. , 2011 -RRB-	3721
the SCI site	3721
Kwon and Tetzlaff	3735
Kwon	3735
Tetzlaff	3744
2001 ; Tetzlaff et al. , 2011	3754
2001	3754
Tetzlaff et al. , 2011	3760
Tetzlaff	3760
et al. , 2011	3769
et al.	3769
2011	3777
The olfactory system	3784
considerable interest	3819
a promising source of cells for transplantation	3844
a promising source	3844
cells for transplantation	3866
cells	3866
transplantation	3876
SCI	3898
its capacity for lifelong regeneration -LRB- Lindsay et al. , 2010 -RRB-	3914
its capacity	3914
lifelong regeneration -LRB- Lindsay et al. , 2010 -RRB-	3931
lifelong regeneration	3931
Lindsay	3954
et al. , 2010	3962
et al.	3962
2010	3970
The main focus of attention in the olfactory tissue	3977
The main focus	3977
attention in the olfactory tissue	3995
attention	3995
the olfactory tissue	4008
a unique type of glia , known as the olfactory ensheathing cells -LRB- OECs -RRB- -LRB- Doucette , 1991 ; Raisman , 2001 ; Ramón-Cueto and Muñoz - Quiles , 2011 -RRB-	4038
a unique type	4038
glia , known as the olfactory ensheathing cells -LRB- OECs -RRB- -LRB- Doucette , 1991 ; Raisman , 2001 ; Ramón-Cueto and Muñoz - Quiles , 2011 -RRB-	4055
glia	4055
the olfactory ensheathing cells -LRB- OECs -RRB- -LRB- Doucette , 1991 ; Raisman , 2001 ; Ramón-Cueto and Muñoz - Quiles , 2011 -RRB-	4070
the olfactory ensheathing cells -LRB- OECs -RRB-	4070
the olfactory ensheathing cells	4070
OECs	4103
Doucette , 1991 ; Raisman , 2001 ; Ramón-Cueto and Muñoz - Quiles , 2011	4110
Doucette	4110
1991 ; Raisman , 2001 ; Ramón-Cueto and Muñoz - Quiles , 2011	4120
1991	4120
Raisman , 2001 ; Ramón-Cueto and Muñoz - Quiles , 2011	4126
Raisman , 2001	4126
Raisman	4126
2001	4135
Ramón-Cueto and Muñoz	4141
Ramón-Cueto	4141
Muñoz	4157
Quiles , 2011	4164
Quiles	4164
2011	4172
These cells	4179
the two main regions of the olfactory axis : peripherally , in the lamina propria and centrally	4205
the two main regions of the olfactory axis	4205
the two main regions	4205
the olfactory axis	4229
the lamina propria	4266
the nerve fiber layer of the olfactory bulb -LRB- OB -RRB- -LRB- Au and Roskams , 2003 -RRB-	4306
the nerve fiber layer	4306
the olfactory bulb -LRB- OB -RRB- -LRB- Au and Roskams , 2003 -RRB-	4331
the olfactory bulb -LRB- OB -RRB-	4331
the olfactory bulb	4331
OB	4351
Au and Roskams	4356
2003	4372
The OECs	4379
an environment which favors neurite outgrowth and the creation of new functional synapses in the central nervous system -LRB- Au and Roskams , 2003 ; Franssen et al. , 2007 -RRB-	4419
an environment	4419
neurite outgrowth and the creation of new functional synapses in the central nervous system -LRB- Au and Roskams , 2003 ; Franssen et al. , 2007 -RRB-	4447
neurite outgrowth	4447
the creation of new functional synapses in the central nervous system -LRB- Au and Roskams , 2003 ; Franssen et al. , 2007 -RRB-	4469
the creation	4469
new functional synapses in the central nervous system -LRB- Au and Roskams , 2003 ; Franssen et al. , 2007 -RRB-	4485
new functional synapses	4485
the central nervous system -LRB- Au and Roskams , 2003 ; Franssen et al. , 2007 -RRB-	4512
the central nervous system	4512
Au and Roskams , 2003 ; Franssen et al. , 2007	4540
Au and Roskams	4540
2003 ; Franssen et al.	4556
2003	4556
Franssen et al.	4562
Franssen	4562
et al.	4571
2007	4579
their supposed axon regenerative properties	4593
their supposed axon	4593
regenerative properties	4613
OECs	4638
animal models of SCI	4676
animal models	4676
SCI	4693
some research	4707
locomotor and axonal regeneration improvements	4731
a consensus on the efficacy of this cellular transplantation andmode of action	4779
a consensus	4779
the efficacy of this cellular transplantation andmode of action	4794
the efficacy	4794
this cellular transplantation andmode of action	4810
this cellular transplantation andmode	4810
action	4851
Barnett and Riddell , 2007 ; Boyd et al. , 2004 ; Franssen et al. , 2008 ; Kubasak et al. , 2008 ; Raisman and Li , 2007 ; Ramón-Cueto and Avila , 1998 ; Ramón-Cueto et al. , 1998 , 2000 ; Tetzlaff et al. , 2011	4881
Barnett and Riddell	4881
2007 ; Boyd et al. , 2004 ; Franssen et al. , 2008 ; Kubasak et al. , 2008 ; Raisman and Li , 2007 ; Ramón-Cueto and Avila , 1998 ; Ramón-Cueto et al. , 1998 , 2000 ; Tetzlaff et al.	4902
2007	4902
Boyd et al. , 2004 ; Franssen et al. , 2008 ; Kubasak et al. , 2008 ; Raisman and Li , 2007 ; Ramón-Cueto and Avila , 1998 ; Ramón-Cueto et al. , 1998 , 2000 ; Tetzlaff et al.	4908
Boyd	4908
et al. , 2004 ; Franssen et al. , 2008 ; Kubasak et al. , 2008 ; Raisman and Li , 2007 ; Ramón-Cueto and Avila , 1998 ; Ramón-Cueto et al. , 1998 , 2000 ; Tetzlaff et al.	4913
et al. , 2004	4913
et al.	4913
2004	4921
Franssen et al. , 2008	4927
Franssen	4927
et al. , 2008	4936
et al.	4936
2008	4944
Kubasak et al. , 2008	4950
Kubasak	4950
et al. , 2008	4958
et al.	4958
2008	4966
Raisman and Li , 2007	4972
Raisman and Li	4972
2007	4988
Ramón-Cueto and Avila , 1998	4994
Ramón-Cueto and Avila	4994
1998	5017
Ramón-Cueto et al. , 1998 , 2000	5023
Ramón-Cueto	5023
et al. , 1998 , 2000	5035
et al.	5035
1998	5043
2000	5049
Tetzlaff et al.	5055
Tetzlaff	5055
et al.	5064
2011	5072
The source of OECs for transplantation into injured spinal cord	5079
The source	5079
OECs for transplantation into injured spinal cord	5093
OECs	5093
transplantation into injured spinal cord	5102
transplantation	5102
injured spinal cord	5123
debate -LRB- Richter et al. , 2005 -RRB-	5162
debate	5162
Richter	5170
et al. , 2005	5178
et al.	5178
2005	5186
the use of olfactory lamina propria -LRB- OLP -RRB- grafts , which is amore accessible source ofOECs in humans ,	5202
the use	5202
olfactory lamina propria -LRB- OLP -RRB- grafts	5213
amore accessible source ofOECs in humans	5260
amore accessible source ofOECs	5260
humans	5294
a safer approach for autologous transplantation -LRB- Bianco et al. , 2004 ; Féron et al. , 1998 ; Franklin , 2002 -RRB-	5315
a safer approach	5315
autologous transplantation -LRB- Bianco et al. , 2004 ; Féron et al. , 1998 ; Franklin , 2002 -RRB-	5336
autologous transplantation	5336
Bianco et al. , 2004 ; Féron et al. , 1998 ; Franklin , 2002	5364
Bianco	5364
et al. , 2004 ; Féron et al. , 1998 ; Franklin , 2002	5371
et al. , 2004	5371
et al.	5371
2004	5379
Féron et al. , 1998	5385
Féron	5385
et al. , 1998	5391
et al.	5391
1998	5399
Franklin , 2002	5405
Franklin	5405
2002	5415
The devastating prognosis associated with the social and economic impacts	5422
The devastating prognosis	5422
the social and economic impacts	5464
increased efforts to find therapies that provide functional recovery for people who undergo severe SCI -LRB- Blight , 2002 ; van den Berg et al. , 2010 -RRB-	5508
therapies that provide functional recovery for people who undergo severe SCI -LRB- Blight , 2002 ; van den Berg et al. , 2010 -RRB-	5534
therapies	5534
functional recovery for people who undergo severe SCI -LRB- Blight , 2002 ; van den Berg et al. , 2010 -RRB-	5557
functional recovery	5557
people who undergo severe SCI -LRB- Blight , 2002 ; van den Berg et al. , 2010 -RRB-	5581
people	5581
severe SCI	5600
Blight , 2002 ; van den Berg et al. , 2010	5612
Blight	5612
2002 ; van den Berg et al.	5620
2002	5620
van den Berg et al.	5626
van den Berg	5626
et al.	5639
2010	5647
previous studies	5667
the use of OLP transplantation	5685
the use	5685
OLP transplantation	5696
a promising , though controversial , repair strategy -LRB- Lu et al. , 2001 , 2002 ; Steward et al. , 2006 -RRB-	5719
a promising , though controversial , repair strategy	5719
Lu et al. , 2001 , 2002 ; Steward et al. , 2006	5771
Lu	5771
et al. , 2001 , 2002 ; Steward et al. , 2006	5774
et al.	5774
2001	5782
2002 ; Steward et al.	5788
2002	5788
Steward et al.	5794
Steward	5794
et al.	5802
2006	5810
the present study	5820
we	5838
the OECs present in OLP grafts	5859
the OECs	5859
OLP grafts	5879
a favorable glial environment that would favor neurite and axonal outgrowth after thoracic spinal cord transection in rats	5903
a favorable glial environment	5903
neurite and axonal outgrowth	5950
thoracic spinal cord transection in rats	5985
thoracic spinal cord transection	5985
rats	6021
OLP transplantation	6033
higher levels of hindlimb motor recovery when	6067
higher levels	6067
hindlimb motor recovery when	6084
hindlimb motor recovery	6084
respiratory lamina propria -LRB- RLP -RRB- , which is a graft devoid of OECs	6125
respiratory lamina propria -LRB- RLP -RRB-	6125
respiratory lamina propria	6125
RLP	6153
a graft devoid of OECs	6168
a graft	6168
OECs	6186
we	6206
the efficacy of OLP transplantation	6216
the efficacy	6216
OLP transplantation	6232
three different therapeutic windows -LRB- acutely , 2 weeks and 4 weeks postinjury -RRB- , since another key aspect in the translation of this therapy to clinical practice is their potential to produce axonal regeneration even when transplantation is delayed after SCI	6255
three different therapeutic windows -LRB- acutely , 2 weeks and 4 weeks postinjury -RRB-	6255
three different therapeutic windows	6255
2 weeks	6301
4 weeks	6313
another key aspect in the translation of this therapy to clinical practice	6340
another key aspect	6340
the translation of this therapy to clinical practice	6362
the translation	6362
this therapy to clinical practice	6381
this therapy	6381
clinical practice	6397
their potential	6418
axonal regeneration	6445
transplantation	6475
SCI	6508
Results Table 1 -- Number and location of fluorogold retrogradely stained cells in the individual rats -LRB- n = 3 -RRB- Table 2 -- Studies performed with several types of olfactory ensheathing cells transplantation in different spinal cord injury models .	6517
Results Table 1	6517
Results	6517
Table 1	6525
Number and location of fluorogold retrogradely stained cells in the individual rats -LRB- n = 3 -RRB- Table 2 -- Studies performed with several types of olfactory ensheathing cells transplantation in different spinal cord injury models	6535
Number and location	6535
fluorogold retrogradely stained cells in the individual rats -LRB- n = 3 -RRB- Table 2 -- Studies performed with several types of olfactory ensheathing cells transplantation in different spinal cord injury models	6558
fluorogold	6558
cells in the individual rats -LRB- n = 3 -RRB- Table 2 -- Studies performed with several types of olfactory ensheathing cells transplantation in different spinal cord injury models	6590
cells	6590
the individual rats	6599
n	6620
3	6622
Table 2 -- Studies performed with several types of olfactory ensheathing cells transplantation in different spinal cord injury models	6626
Table 2	6626
Studies performed with several types of olfactory ensheathing cells transplantation in different spinal cord injury models	6636
Studies	6636
several types of olfactory ensheathing cells transplantation	6659
several types	6659
olfactory ensheathing cells transplantation	6676
different spinal cord injury models	6723
Fig. 1 -- -LRB- A -RRB- BBB scores before -LRB- naive -RRB- and postoperatively at days 5 , 20 , 35 , 50 , 65 , 80 -LRB- 1 -- 6 tests -RRB- after spinal cord transection and acute OLP or RLP transplantation .	6761
Fig. 1	6761
-LRB- A -RRB- BBB scores before -LRB- naive -RRB- and postoperatively at days 5 , 20 , 35 , 50 , 65 , 80 -LRB- 1 -- 6 tests -RRB- after spinal cord transection and acute OLP or RLP transplantation	6770
-LRB- A -RRB- BBB scores before -LRB- naive -RRB- and postoperatively at days 5 , 20 , 35 , 50 , 65 , 80 -LRB- 1 -- 6 tests -RRB- after spinal cord transection and acute OLP	6770
-LRB- A -RRB-	6770
BBB scores	6774
days 5 , 20 , 35 , 50 , 65 , 80 -LRB- 1 -- 6 tests -RRB- after spinal cord transection and acute OLP	6823
days	6823
5	6828
20	6831
35	6835
50	6839
65	6843
80 -LRB- 1 -- 6 tests -RRB-	6847
80	6847
1 -- 6 tests	6851
1	6851
6 tests	6853
spinal cord transection	6868
OLP	6902
RLP transplantation	6909
a -- p < 0.001 for AC and AT groups compared to naive ; b -- p < 0.05 for AC group compared to test 1 ; c -- p < 0.05 for AT compared to test 1 .	6930
a	6930
p < 0.001 for AC and AT groups compared to naive	6932
p	6932
0.001	6934
AC	6944
groups compared to naive	6954
groups	6954
b -- p < 0.05 for AC group compared to test 1 ; c -- p < 0.05 for AT compared to test 1	6980
b	6980
p < 0.05 for AC group compared to test 1 ; c -- p < 0.05 for AT compared to test 1	6982
p <	6982
p	6982
AC group	6993
1 ; c -- p <	7019
1	7019
c	7022
p <	7024
p	7024
<	7025
1	7055
-LRB- B -RRB- BBB scores before -LRB- naive -RRB- and postoperatively at days 5 , 20 , 35 , 50 , 65 , 80 , 95 -LRB- 1 -- 7 tests -RRB- after spinal cord transection and 2-week	7058
-LRB- B -RRB-	7058
BBB scores	7062
days 5 , 20 , 35 , 50 , 65 , 80 , 95 -LRB- 1 -- 7 tests -RRB- after spinal cord transection and 2-week	7111
days 5	7111
20 , 35 , 50 , 65 , 80 , 95 -LRB- 1 -- 7 tests -RRB- after spinal cord transection and 2-week	7119
20	7119
35	7123
50	7127
65	7131
80	7135
95 -LRB- 1 -- 7 tests -RRB- after spinal cord transection	7139
95 -LRB- 1 -- 7 tests -RRB-	7139
95	7139
1 -- 7 tests	7143
1	7143
7 tests	7145
spinal cord transection	7160
2-week	7188
OLP or RLP transplantation	7203
a -- p < 0.001 for 2WDC and 2WDT groups compared to naive ; b -- p < 0.01 for 2WDC and p < 0.05 for 2WDT compared to test 1 .	7231
a	7231
p < 0.001 for 2WDC and 2WDT groups compared to naive	7233
p < 0.001 for 2WDC and 2WDT groups	7233
p	7233
0.001	7235
2WDC and 2WDT groups	7245
b -- p < 0.01 for 2WDC and p < 0.05 for 2WDT compared to test 1	7285
b	7285
p < 0.01 for 2WDC and p < 0.05 for 2WDT compared to test 1	7287
p < 0.01 for 2WDC and p < 0.05 for 2WDT	7287
p	7287
0.01 for 2WDC and p	7289
0.01	7289
2WDC and p	7298
0.05	7309
2WDT	7318
1	7340
-LRB- C -RRB- BBB scores before -LRB- naive -RRB- and postoperatively at days 5 , 20 , 35 , 50 , 65 , 80 , 95 , 110 -LRB- 1 -- 8 tests -RRB- after spinal cord transection and 4-week delayed OLP or RLP transplantation .	7343
-LRB- C -RRB- BBB scores before -LRB- naive -RRB- and postoperatively at days 5 , 20 , 35 , 50 , 65 , 80 , 95 , 110 -LRB- 1 -- 8 tests -RRB- after spinal cord	7343
-LRB- C -RRB-	7343
BBB scores	7347
days 5 , 20 , 35 , 50 , 65 , 80 , 95 , 110 -LRB- 1 -- 8 tests -RRB- after spinal cord	7396
days	7396
5	7401
20	7404
35	7408
50	7412
65	7416
80	7420
95	7424
110 -LRB- 1 -- 8 tests -RRB-	7428
110	7428
1 -- 8 tests	7433
1	7433
8 tests	7435
spinal cord	7450
transection and 4-week delayed OLP or RLP transplantation	7462
transection	7462
4-week delayed OLP or RLP transplantation	7478
a -- p < 0.001 for 4WDC and 4WDT groups compared to naive ; b -- p < 0.05 for 4WDC compared to test 1 ; c -- p < 0.05 for 4WDC group compared to test 1 .	7521
a	7521
p < 0.001 for 4WDC and 4WDT groups compared to naive	7523
p < 0.001 for 4WDC and 4WDT groups	7523
p	7523
0.001	7525
4WDC and 4WDT groups	7535
b -- p < 0.05 for 4WDC compared to test 1 ; c -- p < 0.05 for 4WDC group compared to test 1	7575
b -- p < 0.05 for 4WDC compared to test 1 ; c -- p <	7575
b	7575
p < 0.05 for 4WDC compared to test 1	7577
p <	7577
p	7577
4WDC	7588
1	7610
c -- p <	7613
c	7613
p <	7615
p	7615
<	7616
0.05 for 4WDC group compared to test 1	7617
0.05	7617
4WDC group compared to test 1	7626
4WDC group	7626
1	7654
-LRB- D -RRB- BBB final scores of each experimental group after spinal cord transection and 42 days after OLP or RLP transplantation at different times .	7657
BBB final scores	7661
each experimental group after spinal cord transection and 42 days	7681
each experimental group	7681
spinal cord transection and 42 days	7711
spinal cord transection	7711
42 days	7739
OLP or RLP transplantation	7753
different times	7783
No differences	7800
all experimental groups	7831
p > 0.05	7870
p	7870
> 0.05	7871
>	7871
0.05	7872
Arrows	7879
the time at which the experimental groups underwent OLP or RLP transplantation	7895
the time	7895
the experimental groups	7913
OLP or RLP transplantation	7947
Abbreviations : 2WDC -- 2-Week Delayed Control ; 2WDT -- 2-Week Delayed Treated ; 4WDC -- 4-Week Delayed Control ; 4WDT -- 4-Week Delayed Treated ; AC -- Acute Control ; AT -- Acute Treated ; BBB -- Basso , Beattie , and Bresnahan scale ; OLP -- Olfactory Lamina Propria ; RLP -- Respiratory Lamina Propria .	7975
Abbreviations	7975
2WDC -- 2-Week Delayed Control ; 2WDT -- 2-Week Delayed Treated ; 4WDC -- 4-Week Delayed Control ; 4WDT -- 4-Week Delayed Treated ; AC -- Acute Control ; AT -- Acute Treated ; BBB -- Basso , Beattie , and Bresnahan scale ; OLP -- Olfactory Lamina Propria ; RLP -- Respiratory Lamina Propria	7990
2WDC	7990
2-Week Delayed Control ; 2WDT -- 2-Week Delayed Treated ; 4WDC -- 4-Week Delayed Control ; 4WDT -- 4-Week Delayed Treated ; AC -- Acute Control ; AT -- Acute Treated ; BBB -- Basso , Beattie , and Bresnahan scale ; OLP -- Olfactory Lamina Propria ; RLP -- Respiratory Lamina Propria	7995
2-Week	7995
Control ; 2WDT -- 2-Week Delayed Treated ; 4WDC -- 4-Week Delayed Control ; 4WDT -- 4-Week Delayed Treated ; AC -- Acute Control ; AT -- Acute Treated ; BBB -- Basso , Beattie , and Bresnahan scale ; OLP -- Olfactory Lamina Propria ; RLP -- Respiratory Lamina Propria	8010
Control ; 2WDT -- 2-Week Delayed Treated	8010
Control	8010
2WDT -- 2-Week Delayed Treated	8019
2WDT	8019
2-Week Delayed Treated	8024
2-Week	8024
4WDC -- 4-Week Delayed Control	8048
4WDC	8048
4-Week Delayed Control	8053
4WDT -- 4-Week Delayed Treated	8077
4WDT	8077
4-Week Delayed Treated	8082
4-Week	8082
AC -- Acute Control ; AT -- Acute Treated ; BBB -- Basso	8106
AC -- Acute Control ; AT -- Acute Treated	8106
AC -- Acute Control ; AT -- Acute	8106
AC -- Acute Control ; AT --	8106
AC	8106
Acute Control ; AT	8109
Acute Control	8109
AT	8124
BBB -- Basso	8142
BBB	8142
Basso	8146
Beattie , and Bresnahan scale	8153
Beattie	8153
Bresnahan scale	8166
OLP -- Olfactory Lamina Propria ; RLP --	8183
OLP	8183
Olfactory Lamina Propria ; RLP	8187
Olfactory Lamina Propria	8187
RLP	8213
Respiratory Lamina Propria	8217
Fig. 2 -- -LRB- A -RRB- Spinal cord spared tissue immunostained with GFAP in animals submitted to spinal cord transection and olfactory or respiratory lamina propria transplantation .	8246
Fig. 2	8246
-LRB- A -RRB- Spinal cord spared tissue immunostained with GFAP in animals submitted to spinal cord transection and olfactory or respiratory lamina propria transplantation	8255
-LRB- A -RRB- Spinal cord	8255
A	8256
tissue immunostained with GFAP in animals submitted to spinal cord transection and olfactory or respiratory lamina propria transplantation	8278
tissue immunostained with GFAP in animals submitted to spinal cord transection	8278
tissue	8278
GFAP	8304
animals submitted to spinal cord transection	8312
animals	8312
spinal cord transection	8333
olfactory or respiratory lamina	8361
propria transplantation	8393
No differences	8418
groups -LRB- p > 0.05 -RRB-	8452
groups	8452
p > 0.05	8460
p	8460
> 0.05	8461
>	8461
0.05	8462
-LRB- B -RRB- GAP-43 immunoreactivity in the lesion region of injured rats	8469
-LRB- B -RRB-	8469
GAP-43 immunoreactivity	8473
the lesion region of injured rats	8500
the lesion region	8500
injured rats	8521
both types of lamina propria	8552
both types	8552
lamina propria	8566
No differences	8582
groups -LRB- p > 0.05 -RRB-	8616
groups	8616
p > 0.05	8624
p	8624
> 0.05	8625
>	8625
0.05	8626
-LRB- C -RRB- Representative longitudinal spinal cord section	8633
-LRB- C -RRB-	8633
Representative longitudinal spinal cord section	8637
GAP-43	8702
the lesion site	8718
-LRB- D -RRB- Higher magnificationof	8735
-LRB- D -RRB-	8735
Higher magnificationof	8739
the highlighted box , showing GAP-43 positive sprouting axons	8762
the highlighted box	8762
GAP-43	8791
axons	8817
arrows	8824
Magnification -- 100 × , scale bar -- 100 μm .	8832
Magnification	8832
100 × , scale bar -- 100 μm	8846
100 × , scale bar	8846
100 ×	8846
scale bar	8852
100 μm	8862
Abbreviations : GAP-43 -- Growth Associated Protein-43 ; GFAP -- Glial Fibrillary Acidic Protein .	8870
Abbreviations	8870
GAP-43 -- Growth Associated Protein-43 ; GFAP -- Glial Fibrillary Acidic Protein	8885
GAP-43	8885
Growth Associated Protein-43 ; GFAP	8892
Growth Associated Protein-43	8892
GFAP	8922
Glial Fibrillary Acidic Protein	8927
Fig. 3 -- 5-HT and CGRP fiber regeneration in a representative animal with moderate cavitation at the lesion site , approximately 18 weeks after spinal cord transection .	8961
Fig. 3	8961
5-HT and CGRP fiber regeneration in a representative animal with moderate cavitation at the lesion site , approximately 18 weeks after spinal cord transection	8970
5-HT and CGRP fiber regeneration	8970
a representative animal with moderate cavitation at the lesion site , approximately 18 weeks	9006
a representative animal	9006
moderate cavitation at the lesion site , approximately 18 weeks	9035
moderate cavitation	9035
the lesion site	9058
approximately 18 weeks	9075
spinal cord transection	9104
-LRB- A -RRB- There are 5-HT fibers surrounding themargin of the transection site in the rostral stump -LRB- arrows -RRB- , but themajority of these sprouts	9129
-LRB- A -RRB-	9129
There	9133
5-HT fibers surrounding themargin of the transection site in the rostral stump -LRB- arrows -RRB- , but themajority of these sprouts	9143
5-HT fibers	9143
themargin of the transection site in the rostral stump -LRB- arrows -RRB- , but themajority of these sprouts	9167
themargin of the transection site in the rostral stump -LRB- arrows -RRB-	9167
themargin	9167
the transection site in the rostral stump -LRB- arrows -RRB-	9180
the transection site	9180
the rostral stump -LRB- arrows -RRB-	9204
the rostral stump	9204
arrows	9223
themajority of these sprouts	9236
themajority	9236
these sprouts	9251
the GFAP-negative lesion area -LRB- asterisk -RRB-	9284
the GFAP-negative lesion area	9284
asterisk	9315
5-HT fibers	9326
the caudal stump	9354
-LRB- B -RRB- CGRP fibers	9372
-LRB- B -RRB-	9372
CGRP fibers	9376
the border of the transection site in both stumps -LRB- arrows -RRB-	9410
the border	9410
the transection site in both stumps -LRB- arrows -RRB-	9424
the transection site	9424
both stumps -LRB- arrows -RRB-	9448
both stumps	9448
arrows	9461
the GFAP-negative lesion area -LRB- asterisk -RRB-	9485
the GFAP-negative lesion area	9485
asterisk	9516
Rostral	9527
the left	9541
Photomontagesweremade fromdigital images withmagnification of 100 × , 2.2 μmof optical	9551
Photomontagesweremade fromdigital images	9551
100 × , 2.2 μmof optical	9613
2.2 μmof optical	9619
2.2	9619
thickness and 11 confocal planes	9642
thickness	9642
11 confocal planes	9656
Pixel size -- 638.92 × 638.92 μm .	9676
Pixel size	9676
638.92	9687
638.92 μm	9694
Scale bar -- 500 μm .	9705
Scale bar	9705
500 μm	9715
Abbreviations : 5-HT -- Serotonin ; CGRP -- Calcitonin gene-related peptide ; GFAP -- Glial Fibrillary Acidic Protein .	9723
Abbreviations	9723
5-HT -- Serotonin	9738
5-HT	9738
Serotonin	9743
CGRP -- Calcitonin gene-related peptide ; GFAP -- Glial Fibrillary Acidic Protein	9754
CGRP	9754
Calcitonin gene-related peptide ; GFAP	9759
Calcitonin gene-related peptide	9759
GFAP	9792
Glial Fibrillary Acidic Protein	9797
Fig. 4 -- Longitudinal spinal cord sections , double-stained for 5-HT -LRB- red -RRB- and GFAP -LRB- green -RRB- at approximately 18 weeks post-injury .	9831
Fig. 4	9831
Longitudinal spinal cord sections , double-stained for 5-HT -LRB- red -RRB- and GFAP -LRB- green -RRB- at approximately 18 weeks post-injury	9840
Longitudinal spinal cord sections	9840
double-stained for 5-HT -LRB- red -RRB- and GFAP -LRB- green -RRB- at approximately 18 weeks post-injury	9875
5-HT -LRB- red -RRB- and GFAP -LRB- green -RRB-	9894
5-HT	9894
red	9900
GFAP	9909
approximately 18 weeks	9925
AC group -LRB- A -- C -RRB- , AT group -LRB- D -- F -RRB- , 2WDC group -LRB- G -- I -RRB- , 2WDT group -LRB- J -- L -RRB- , 4WDC group -LRB- M -- O -RRB- and 4WDT group -LRB- P -- R -RRB- .	9961
AC	9961
group -LRB- A -- C -RRB- , AT group -LRB- D -- F -RRB- , 2WDC group -LRB- G -- I -RRB- , 2WDT group -LRB- J -- L -RRB- , 4WDC group -LRB- M -- O -RRB- and 4WDT group -LRB- P -- R -RRB-	9964
group -LRB- A -- C -RRB-	9964
group	9964
A -- C	9971
A	9971
C	9973
AT group -LRB- D -- F -RRB-	9977
AT group	9977
D -- F	9987
D	9987
F	9989
2WDC group -LRB- G -- I -RRB-	9993
2WDC group	9993
G -- I	10005
G	10005
I	10007
2WDT group -LRB- J -- L -RRB-	10011
2WDT group	10011
J -- L	10023
J	10023
L	10025
4WDC group -LRB- M -- O -RRB-	10029
4WDC group	10029
M -- O	10041
M	10041
O	10043
4WDT group -LRB- P -- R -RRB-	10050
4WDT group	10050
P -- R	10062
P	10062
R	10064
rostral stump -LRB- dashed lines represents the lesion border -RRB- ; Center -- lesion epicenter -LRB- GFAP negative -RRB- ; Right -- caudal stump .	10073
rostral stump -LRB- dashed lines represents the lesion border -RRB- ; Center -- lesion epicenter -LRB- GFAP negative -RRB-	10073
rostral stump -LRB- dashed lines represents the lesion border -RRB-	10073
rostral stump	10073
lines	10095
the lesion border	10112
Center -- lesion epicenter -LRB- GFAP negative -RRB-	10132
Center	10132
lesion epicenter -LRB- GFAP negative -RRB-	10139
lesion epicenter	10139
GFAP	10157
caudal stump	10179
Themajority of 5-HT axons	10193
Themajority	10193
5-HT axons	10208
rostral non-injured areas	10235
the border of the scar	10276
the border	10276
the scar	10290
the absence of 5-HT axon immunoreactivity in the lesion epicenter	10305
the absence	10305
5-HT axon immunoreactivity in the lesion epicenter	10320
5-HT axon immunoreactivity	10320
the lesion epicenter	10350
caudal stump.Arrows	10375
5-HT fibers	10404
Arrowheads	10417
astrocytic cell body	10437
Magnification -- 40 × .	10459
Magnification	10459
40 ×	10473
Optical	10478
thickness -- 0.69 μm	10492
thickness	10492
0.69 μm	10502
Pixel size -- 397 × 397 μm .	10511
Pixel size	10511
397 × 397 μm	10522
397 ×	10522
397 μm	10526
Scale bar -- 50 μm .	10534
Scale bar	10534
50 μm	10544
Abbreviations : 2WDC -- 2-Week Delayed Control ; 2WDT -- 2-Week Delayed Treated ; 4WDC -- 4-Week Delayed Control ; 4WDT -- 4-Week Delayed Treated ; 5-HT -- Serotonin ; AC -- Acute Control ; AT -- Acute Treated ; GFAP -- Glial Fibrillary Acidic Protein .	10551
Abbreviations	10551
2WDC -- 2-Week Delayed Control ; 2WDT -- 2-Week Delayed Treated ; 4WDC -- 4-Week Delayed Control ; 4WDT -- 4-Week Delayed Treated	10566
2WDC	10566
2-Week Delayed Control ; 2WDT -- 2-Week Delayed Treated ; 4WDC -- 4-Week Delayed Control ; 4WDT -- 4-Week Delayed Treated	10571
2-Week Delayed Control ; 2WDT --	10571
2-Week Delayed Control	10571
2WDT	10595
2-Week Delayed Treated ; 4WDC -- 4-Week Delayed Control ; 4WDT -- 4-Week Delayed Treated	10600
2-Week	10600
4WDC -- 4-Week Delayed Control ; 4WDT -- 4-Week Delayed	10624
4WDC	10624
4-Week Delayed Control ; 4WDT	10629
4-Week	10629
Control ; 4WDT	10644
Control	10644
4WDT	10653
5-HT -- Serotonin ; AC -- Acute Control	10682
5-HT	10682
Serotonin ; AC	10687
Serotonin	10687
AC	10698
Acute Control	10701
AT -- Acute Treated ; GFAP -- Glial Fibrillary Acidic Protein	10716
AT	10716
Acute Treated	10719
Acute	10719
GFAP -- Glial Fibrillary Acidic Protein	10734
GFAP	10734
Glial Fibrillary Acidic Protein	10739
Fig. 5 -- Longitudinal spinal cord sections , double-stained for CGRP -LRB- red -RRB- and GFAP -LRB- green -RRB- at approximately 18 weeks post-injury .	10773
Fig. 5	10773
Longitudinal spinal cord sections , double-stained for CGRP -LRB- red -RRB- and GFAP -LRB- green -RRB- at approximately 18 weeks post-injury	10782
Longitudinal spinal cord sections	10782
double-stained for CGRP -LRB- red -RRB- and GFAP -LRB- green -RRB- at approximately 18 weeks post-injury	10817
CGRP -LRB- red -RRB- and GFAP -LRB- green -RRB-	10836
CGRP	10836
red	10842
GFAP	10851
approximately 18 weeks	10867
AC group -LRB- A -- C -RRB- , AT group -LRB- D -- F -RRB- , 2WDC group -LRB- G -- I -RRB- , 2WDT group -LRB- J -- L -RRB- , 4WDC group -LRB- M -- O -RRB- and 4WDT group -LRB- P -- R -RRB- .	10903
AC	10903
group -LRB- A -- C -RRB- , AT group -LRB- D -- F -RRB- , 2WDC group -LRB- G -- I -RRB- , 2WDT group -LRB- J -- L -RRB- , 4WDC group -LRB- M -- O -RRB- and 4WDT group -LRB- P -- R -RRB-	10906
group -LRB- A -- C -RRB-	10906
group	10906
A -- C	10913
A	10913
C	10915
AT group -LRB- D -- F -RRB-	10919
AT group	10919
D -- F	10929
D	10929
F	10931
2WDC group -LRB- G -- I -RRB-	10935
2WDC group	10935
G -- I	10947
G	10947
I	10949
2WDT group -LRB- J -- L -RRB-	10953
2WDT group	10953
J -- L	10965
J	10965
L	10967
4WDC group -LRB- M -- O -RRB-	10971
4WDC group	10971
M -- O	10983
M	10983
O	10985
4WDT group -LRB- P -- R -RRB-	10992
4WDT group	10992
P -- R	11004
P	11004
R	11006
rostral stump -LRB- dashed lines represents the lesion border -RRB- ; Center -- lesion epicenter -LRB- GFAP negative -RRB- ; Right -- caudal stump .	11015
rostral stump -LRB- dashed lines represents the lesion border -RRB- ; Center -- lesion epicenter -LRB- GFAP negative -RRB-	11015
rostral stump -LRB- dashed lines represents the lesion border -RRB-	11015
rostral stump	11015
lines	11037
the lesion border	11054
Center -- lesion epicenter -LRB- GFAP negative -RRB-	11074
Center	11074
lesion epicenter -LRB- GFAP negative -RRB-	11081
lesion epicenter	11081
GFAP	11099
caudal stump	11121
the presence of CGRP axon immunoreactivity in the lesion epicenter , rostral and caudal stumps	11140
the presence	11140
CGRP axon immunoreactivity in the lesion epicenter , rostral and caudal stumps	11156
CGRP axon immunoreactivity	11156
the lesion epicenter , rostral and caudal stumps	11186
the lesion epicenter	11186
rostral	11208
caudal stumps	11220
Arrows	11235
CGRP fibers	11251
Arrowheads	11264
astrocytic cell body	11284
Magnification -- 40 × .	11306
Magnification	11306
40 ×	11320
Optical	11325
thickness -- 0.69 μm	11339
thickness	11339
0.69 μm	11349
Pixel size -- 397 × 397 μm .	11358
Pixel size	11358
397 × 397 μm	11369
397 ×	11369
397 μm	11373
Scale bar -- 50 μm .	11381
Scale bar	11381
50 μm	11391
Abbreviations : 2WDC -- 2-WeekDelayed Control ; 2WDT -- 2-WeekDelayed Treated ; 4WDC -- 4-Week Delayed Control ; 4WDT -- 4-Week Delayed Treated ; AC -- Acute Control ; AT -- Acute Treated ; CGRP -- Calcitonin gene-related peptide ; GFAP -- Glial Fibrillary Acidic Protein .	11398
Abbreviations	11398
2WDC -- 2-WeekDelayed Control ; 2WDT -- 2-WeekDelayed Treated ; 4WDC -- 4-Week Delayed Control ; 4WDT -- 4-Week Delayed Treated	11413
2WDC	11413
2-WeekDelayed Control ; 2WDT	11418
2-WeekDelayed Control	11418
2WDT	11441
2-WeekDelayed Treated ; 4WDC -- 4-Week Delayed Control ; 4WDT -- 4-Week Delayed	11446
2-WeekDelayed	11446
4WDC -- 4-Week Delayed Control ; 4WDT -- 4-Week Delayed	11469
4WDC	11469
4-Week Delayed Control ; 4WDT	11474
4-Week	11474
Control ; 4WDT	11489
Control	11489
4WDT	11498
AC -- Acute Control	11527
AC	11527
Acute Control	11530
AT -- Acute Treated ; CGRP -- Calcitonin gene-related peptide ; GFAP -- Glial Fibrillary Acidic Protein	11545
AT	11545
Acute Treated	11548
Acute	11548
CGRP -- Calcitonin gene-related peptide ; GFAP -- Glial Fibrillary Acidic Protein	11563
CGRP	11563
Calcitonin gene-related peptide ; GFAP	11568
Calcitonin gene-related peptide	11568
GFAP	11601
Glial Fibrillary Acidic Protein	11606
Fig. 6 -- Quantitative data of 5-HT -LRB- A -- C -RRB- and CGRP -LRB- D -- E -RRB- axon profiles in rostral -LRB- above -RRB- , lesion -LRB- center -RRB- and caudal -LRB- below -RRB- regions of spinal cord at approximately 18 weeks post-injury .	11640
Fig. 6	11640
Quantitative data of 5-HT -LRB- A -- C -RRB- and CGRP -LRB- D -- E -RRB-	11649
Quantitative data	11649
5-HT -LRB- A -- C -RRB- and CGRP -LRB- D -- E -RRB-	11670
5-HT	11670
A -- C	11676
A	11676
C	11678
CGRP	11685
D -- E	11691
D	11691
E	11693
axon profiles in rostral -LRB- above -RRB- , lesion -LRB- center -RRB- and caudal -LRB- below -RRB-	11696
axon profiles	11696
rostral -LRB- above -RRB- , lesion -LRB- center -RRB- and caudal -LRB- below -RRB-	11713
rostral -LRB- above -RRB-	11713
rostral	11713
lesion -LRB- center -RRB-	11730
lesion	11730
center	11738
caudal -LRB- below -RRB-	11750
caudal	11750
regions of spinal cord at approximately 18 weeks post-injury	11765
regions	11765
spinal cord at approximately 18 weeks post-injury	11776
spinal cord	11776
approximately 18 weeks post-injury	11791
approximately 18 weeks	11791
There	11827
no statistical differences between groups transplanted with olfactory or respiratory lamina propria in the studied fibers -LRB- p > 0.05 -RRB-	11838
no statistical differences	11838
groups transplanted with olfactory or respiratory lamina propria in the studied fibers -LRB- p > 0.05 -RRB-	11873
groups	11873
olfactory or respiratory lamina propria	11898
the studied fibers -LRB- p > 0.05 -RRB-	11941
the studied fibers	11941
p > 0.05	11961
p	11961
> 0.05	11962
>	11962
0.05	11963
Abbreviations : 5-HT -- Serotonin ; CGRP -- Calcitonin gene-related peptide .	11970
Abbreviations	11970
5-HT -- Serotonin ; CGRP -- Calcitonin gene-related peptide	11985
5-HT	11985
Serotonin ; CGRP	11990
Serotonin	11990
CGRP	12001
Calcitonin gene-related peptide	12006
Fig. 7 -- -LRB- A -RRB- Illustration of the cavity formed as a result of the spinal cord injury procedure -LRB- left , arrow -RRB- and appearance of the transplanted olfactory or respiratory lamina propria in the lesion gap -LRB- right , arrow -RRB- .	12040
Fig. 7	12040
-LRB- A -RRB- Illustration of the cavity formed as a result of the spinal cord injury procedure -LRB- left , arrow -RRB- and appearance of the transplanted olfactory or respiratory lamina propria in the lesion gap -LRB- right , arrow -RRB-	12049
-LRB- A -RRB- Illustration	12049
-LRB- A -RRB-	12049
Illustration	12053
the cavity formed as a result of the spinal cord injury procedure -LRB- left , arrow -RRB- and appearance of the transplanted olfactory or respiratory lamina propria in the lesion gap -LRB- right , arrow -RRB-	12069
the cavity	12069
a result of the spinal cord injury procedure -LRB- left , arrow -RRB- and appearance of the transplanted olfactory or respiratory lamina propria in the lesion gap -LRB- right , arrow -RRB-	12090
a result of the spinal cord injury procedure -LRB- left , arrow -RRB-	12090
a result	12090
the spinal cord injury procedure -LRB- left , arrow -RRB-	12102
the spinal cord injury procedure	12102
left , arrow	12136
left	12136
arrow	12142
appearance of the transplanted olfactory or respiratory lamina propria in the lesion gap -LRB- right , arrow -RRB-	12153
appearance	12153
the transplanted olfactory or respiratory lamina propria in the lesion gap -LRB- right , arrow -RRB-	12167
the transplanted olfactory or respiratory lamina	12167
propria	12216
the lesion gap -LRB- right , arrow -RRB-	12227
the lesion gap	12227
right , arrow	12243
right	12243
arrow	12250
-LRB- B -RRB- Macroscopic view of the spinal cords from different animal groups .	12258
-LRB- B -RRB-	12258
Macroscopic view of the spinal cords from different animal groups	12262
Macroscopic view	12262
the spinal cords from different animal groups	12282
the spinal cords	12282
different animal groups	12304
the transection site	12339
transplanted tissue	12375
these transplants	12399
a gap between the rostral -LRB- left -RRB- and caudal segments	12424
a gap	12424
the rostral -LRB- left -RRB- and caudal segments	12438
the rostral -LRB- left -RRB-	12438
the rostral	12438
left	12451
caudal segments	12461
Fig. 8 -- -LRB- A -RRB- Olfactory and -LRB- B -RRB- respiratory mucosa dissected from nasal septum of adult rat , immunostained by GFAP -LRB- first column -RRB- , p75 -LRB- second column -RRB- and S-100 -LRB- third column -RRB- .	12480
Fig. 8	12480
-LRB- A -RRB- Olfactory and -LRB- B -RRB- respiratory mucosa dissected from nasal septum of adult rat , immunostained by GFAP -LRB- first column -RRB- , p75 -LRB- second column -RRB- and S-100 -LRB- third column -RRB-	12489
-LRB- A -RRB-	12489
-LRB- B -RRB- respiratory mucosa dissected from nasal septum of adult rat , immunostained by GFAP -LRB- first column -RRB- , p75 -LRB- second column -RRB- and S-100 -LRB- third column -RRB-	12507
-LRB- B -RRB- respiratory mucosa	12507
B	12508
nasal septum of adult rat , immunostained by GFAP -LRB- first column -RRB- , p75 -LRB- second column -RRB- and S-100 -LRB- third column -RRB-	12545
nasal septum	12545
adult rat	12561
GFAP -LRB- first column -RRB- , p75 -LRB- second column -RRB- and S-100 -LRB- third column -RRB-	12589
GFAP -LRB- first column -RRB-	12589
GFAP	12589
first column	12595
p75 -LRB- second column -RRB-	12610
p75	12610
second column	12615
S-100 -LRB- third column -RRB-	12634
S-100	12634
third column	12641
Olfactory ensheathing cells	12656
immunoreactivity	12703
the three markers used -LRB- arrows -RRB-	12724
the three markers	12724
-LRB- arrows -RRB-	12747
Respiratory lamina propria	12757
olfactory ensheathing cells	12797
Asterisks	12826
olfactory epithelium	12845
Magnification -- 600 × -LRB- water objective -RRB- .	12867
Magnification	12867
600 × -LRB- water objective -RRB-	12881
water objective	12887
Pixel size -- 265 × 265 μm -LRB- A -- 0.57 μmoptical stack thickness and 44 confocal planes ; B -- 1.0 μm optical stack thickness and 21 confocal planes -RRB- .	12905
Pixel size	12905
265 × 265 μm -LRB- A -- 0.57 μmoptical stack thickness and 44 confocal planes ; B -- 1.0 μm optical stack thickness and 21 confocal planes -RRB-	12916
265 ×	12916
265 μm -LRB- A -- 0.57 μmoptical stack thickness and 44 confocal planes ; B -- 1.0 μm optical stack thickness and 21 confocal planes -RRB-	12920
265 μm	12920
A -- 0.57	12928
0.57	12930
thickness and 44 confocal planes ; B -- 1.0 μm optical stack thickness and 21 confocal planes	12951
thickness and 44 confocal planes	12951
thickness	12951
44 confocal planes	12965
B -- 1.0 μm optical stack thickness and 21 confocal planes	12985
B	12985
1.0 μm optical stack thickness and 21 confocal planes	12987
1.0 μm	12987
optical	12994
thickness and 21 confocal planes	13008
thickness	13008
21 confocal planes	13022
Scale bar -- 20 μm .	13043
Scale bar	13043
20 μm	13053
-LRB- C -RRB- Olfactory and -LRB- D -RRB- respiratory lamina propria at the site of spinal cord transection	13060
-LRB- C -RRB- Olfactory and -LRB- D -RRB- respiratory lamina propria	13060
-LRB- C -RRB- Olfactory	13060
-LRB- C -RRB-	13060
D	13079
respiratory lamina propria	13082
the site of spinal cord transection	13112
the site	13112
spinal cord transection	13124
GFAP -LRB- first column -RRB- , p75 -LRB- second column -RRB- and S-100 -LRB- third column -RRB-	13166
GFAP -LRB- first column -RRB-	13166
GFAP	13166
first column	13172
p75 -LRB- second column -RRB-	13187
p75	13187
second column	13192
S-100 -LRB- third column -RRB-	13211
S-100	13211
third column	13218
Olfactory ensheathing	13233
their fusiform aspect	13271
the same threemarkers observed before transplantation -LRB- arrows -RRB-	13318
the same threemarkers	13318
transplantation -LRB- arrows -RRB-	13356
transplantation	13356
arrows	13373
Respiratory lamina propria	13382
olfactory ensheathing cells	13427
Magnification -- 400 × .	13456
Magnification	13456
400 ×	13470
Pixel size -- 497 × 497 μm -LRB- C -- 0.76 μm optical stack thickness and 21 confocal planes ; D -- 0.1 μm optical stack thickness and 14 confocal planes -RRB- .	13476
Pixel size	13476
497 × 497 μm -LRB- C -- 0.76 μm optical stack thickness and 21 confocal planes ; D -- 0.1 μm optical stack thickness and 14 confocal planes -RRB-	13487
497 ×	13487
497 μm -LRB- C -- 0.76 μm optical stack thickness and 21 confocal planes ; D -- 0.1 μm optical stack thickness and 14 confocal planes -RRB-	13491
497 μm	13491
C -- 0.76 μm optical stack thickness and 21 confocal planes ; D -- 0.1 μm optical stack thickness and 14 confocal planes	13499
C -- 0.76 μm optical stack thickness and 21 confocal planes ; D --	13499
C	13499
0.76 μm optical stack thickness and 21 confocal planes ; D	13501
0.76 μm	13501
optical	13509
thickness and 21 confocal planes ; D	13523
thickness and 21 confocal planes	13523
thickness	13523
21 confocal planes	13537
D	13557
0.1 μm optical stack thickness and 14 confocal planes	13559
0.1 μm	13559
optical	13566
thickness and 14 confocal planes	13580
thickness	13580
14 confocal planes	13594
Scale bar -- 20 μm .	13615
Scale bar	13615
20 μm	13625
Abbreviations : GFAP -- Glial Fibrillary Acidic Protein , p75 -- p75 Neurotrophin Receptor .	13632
Abbreviations	13632
GFAP -- Glial Fibrillary Acidic Protein , p75 -- p75 Neurotrophin Receptor	13647
GFAP	13647
Glial Fibrillary Acidic Protein , p75	13652
Glial Fibrillary Acidic Protein	13652
p75	13685
p75 Neurotrophin Receptor	13689
2.1	13717
Hindlimb motor function Fig. 1	13722
Hindlimb motor function Fig.	13722
1	13751
average Basso , Beattie , and Bresnahan scale scores -LRB- BBB -RRB- before and across the post-injury survival interval for the experimental groups	13765
average Basso	13765
Beattie	13780
Bresnahan scale scores -LRB- BBB -RRB- before and across the post-injury survival interval for the experimental groups	13793
Bresnahan scale scores -LRB- BBB -RRB-	13793
Bresnahan scale scores	13793
BBB	13817
the post-injury survival interval for the experimental groups	13840
the post-injury survival interval	13840
the experimental groups	13878
the injury -LRB- naive test -RRB-	13912
the injury	13912
naive test	13924
no differences	13937
the average of inter-group BBB scores	13969
the average	13969
inter-group BBB scores	13984
the animals	14011
normal locomotor activity -LRB- scored as 21 -RRB-	14030
normal locomotor activity	14030
21	14067
contrast	14075
5 days post-injury -LRB- test 1 -RRB-	14088
5 days post-injury	14088
test 1	14108
there	14116
a complete flaccid paralysis of both hindlimbsmovements in most animals	14126
a complete flaccid paralysis	14126
both hindlimbsmovements in most animals	14158
both hindlimbsmovements	14158
most animals	14185
BBB scores	14202
0.21 ± 0.09	14218
0.21	14218
0.09	14223
the acute control group -LRB- AC -RRB-	14232
the acute control group	14232
AC	14257
0.23 ± 0.16	14262
0.23	14262
0.16	14267
the acute treated group -LRB- AT -RRB-	14276
the acute treated group	14276
0.18	14306
0.09	14311
the 2-week delayed control group -LRB- 2WDC -RRB- , 0.21 ± 0.09 for the 2-week delayed treated group -LRB- 2WDT -RRB- , 0.16 ± 0.09 for the 4-week control group -LRB- 4WDC -RRB- , 0.41 ± 0.37 for the 4-week treated group -LRB- 4WDT -RRB- -LRB- mean ± SEM -RRB-	14320
the 2-week delayed control group -LRB- 2WDC -RRB-	14320
the 2-week delayed control group	14320
2WDC	14354
0.21 ± 0.09 for the 2-week delayed treated group -LRB- 2WDT -RRB- , 0.16 ± 0.09 for the 4-week control group -LRB- 4WDC -RRB- , 0.41 ± 0.37 for the 4-week treated group -LRB- 4WDT -RRB- -LRB- mean ± SEM -RRB-	14361
0.21 ± 0.09	14361
0.21	14361
0.09	14367
the 2-week delayed treated group -LRB- 2WDT -RRB- , 0.16 ± 0.09 for the 4-week control group -LRB- 4WDC -RRB- , 0.41 ± 0.37 for the 4-week treated group -LRB- 4WDT -RRB- -LRB- mean ± SEM -RRB-	14376
2-week delayed treated group -LRB- 2WDT -RRB-	14380
2-week delayed treated group	14380
2WDT	14410
0.16 ± 0.09 for the 4-week control group -LRB- 4WDC -RRB-	14417
0.16 ± 0.09	14417
0.16	14417
0.09	14422
the 4-week control group -LRB- 4WDC -RRB-	14431
the 4-week control group	14431
4WDC	14457
0.41 ± 0.37 for the 4-week treated group -LRB- 4WDT -RRB- -LRB- mean ± SEM -RRB-	14464
0.41 ± 0.37	14464
0.41	14464
0.37	14469
the 4-week treated group -LRB- 4WDT -RRB- -LRB- mean ± SEM -RRB-	14478
the 4-week treated group -LRB- 4WDT -RRB-	14478
the 4-week treated group	14478
4WDT	14504
SEM	14516
the slight recovery ofmotor skills observed from 20 days after SCI to the end of this study	14533
the slight recovery ofmotor skills	14533
20 days	14582
SCI	14596
the end of this study	14603
the end	14603
this study	14614
there	14626
no differences between the average BBB scores obtained at any time point comparing acute , 2-week or 4-week OLP transplanted groups with their respective RLP control groups -LRB- one-way repeated measures ANOVA ; acute groups F -LRB- 1,20 -RRB- = 0.13 , p > 0.05 ; 2-week delayed groups F -LRB- 1,22 -RRB- = 1.66 , p > 0.05 ; 4-week delayed groups F -LRB- 1,22 -RRB- = 0.11 , p > 0.05 -RRB-	14637
no differences between the average BBB scores	14637
no differences	14637
the average BBB scores	14660
any time point	14695
OLP transplanted groups with their respective RLP control groups	14744
OLP transplanted groups	14744
their respective RLP control groups	14773
one-way repeated measures ANOVA ; acute groups F -LRB- 1,20 -RRB- = 0.13 , p > 0.05 ; 2-week delayed groups F -LRB- 1,22 -RRB- = 1.66 , p > 0.05 ; 4-week delayed groups F -LRB- 1,22 -RRB- = 0.11 , p > 0.05	14810
one-way	14810
measures ANOVA ; acute groups F -LRB- 1,20 -RRB- = 0.13 , p > 0.05 ; 2-week delayed groups F -LRB- 1,22 -RRB- = 1.66 , p > 0.05 ; 4-week delayed groups F -LRB- 1,22 -RRB- = 0.11 , p >	14827
measures ANOVA	14827
measures	14827
ANOVA	14836
acute groups F -LRB- 1,20 -RRB- = 0.13	14843
acute groups F -LRB- 1,20 -RRB-	14843
acute groups F	14843
1,20	14858
0.13	14864
p > 0.05	14870
p >	14870
p	14870
0.05	14872
2-week delayed groups F -LRB- 1,22 -RRB- = 1.66	14878
2-week delayed groups F -LRB- 1,22 -RRB-	14878
2-week delayed groups F	14878
1,22	14902
1.66	14908
p > 0.05	14914
p >	14914
p	14914
0.05	14916
4-week delayed groups F -LRB- 1,22 -RRB- = 0.11	14922
4-week delayed groups F -LRB- 1,22 -RRB-	14922
4-week delayed groups F	14922
1,22	14946
0.11	14952
p >	14958
p	14958
>	14959
the last functional test	14970
the BBB scores	14996
3.5 ± 0.9	15016
the AC group ; 2.7 ± 0.5 for theAT group ; 2.6 ± 0.4 for the2WDC group ; 3.0 ± 0.6 for the 2WDT group ; 2.6 ± 0.6 for the 4WDC group and 2.0 ± 0.4 for the 4WDT group	15028
the AC group ; 2.7 ± 0.5 for theAT group ; 2.6 ± 0.4 for the2WDC group ; 3.0 ± 0.6 for the 2WDT group ; 2.6 ± 0.6 for the 4WDC group and 2.0 ± 0.4	15028
the AC group	15028
2.7	15042
0.5 for theAT group ; 2.6 ± 0.4 for the2WDC group ; 3.0 ± 0.6 for the 2WDT group ; 2.6 ± 0.6 for the 4WDC group and 2.0 ± 0.4	15046
0.5 for theAT group ; 2.6 ± 0.4 for the2WDC group ; 3.0 ± 0.6 for the 2WDT group ; 2.6 ± 0.6	15046
0.5 for theAT group	15046
0.5	15046
theAT group	15054
2.6 ± 0.4 for the2WDC group	15067
2.6 ±	15067
0.4 for the2WDC group	15071
0.4	15071
the2WDC group	15079
3.0 ± 0.6 for the 2WDT group	15094
3.0 ±	15094
0.6 for the 2WDT group	15098
0.6	15098
the 2WDT group	15106
2.6 ± 0.6	15122
2.6 ±	15122
0.6	15126
the 4WDC group and 2.0 ± 0.4	15134
the 4WDT group	15165
No differences	15181
data from the last functional test	15212
data	15212
the last functional test	15222
all the studied groups -LRB- one-way ANOVA F -LRB- 5,65 -RRB- = 0.57 , p > 0.05 -RRB-	15269
all the studied groups	15269
one-way ANOVA F -LRB- 5,65 -RRB- = 0.57 , p > 0.05	15293
one-way ANOVA F -LRB- 5,65 -RRB- = 0.57 , p >	15293
one-way ANOVA F -LRB- 5,65 -RRB- = 0.57	15293
one-way ANOVA F -LRB- 5,65 -RRB-	15293
one-way ANOVA F	15293
5,65	15309
0.57	15315
p >	15321
p	15321
0.05	15323
2.2	15330
Spinal tissue sparing and sprouting Analysis of the glial fibrillary acidic protein -LRB- GFAP -RRB-	15335
Spinal tissue sparing	15335
sprouting Analysis	15361
the glial fibrillary acidic protein -LRB- GFAP -RRB-	15383
the glial fibrillary acidic protein	15383
GFAP	15420
immunoreactive sections	15426
a variation	15459
themorphology of the lesion sites	15474
themorphology	15474
the lesion sites	15491
the experimental groups	15514
some rats	15539
transparent cavities that separated their spinal cord stumps , while others contained smaller cavities	15559
transparent cavities	15559
their spinal cord stumps	15595
others	15627
smaller cavities	15644
The preserved tissue area , determined by the presence of healthy looking cells and GFAP immunoreactivity ,	15662
The preserved tissue area	15662
the presence of healthy looking cells and GFAP immunoreactivity	15703
the presence	15703
healthy looking cells and GFAP immunoreactivity	15719
healthy looking cells	15719
GFAP immunoreactivity	15745
the repair effects produced by OLP or RLP transplantation	15793
the repair effects	15793
OLP or RLP transplantation	15824
no significant differences	15861
the groups -LRB- oneway ANOVA F -LRB- 5,21 -RRB- = 0.75 , p > 0.05 -RRB-	15907
the groups	15907
oneway ANOVA F -LRB- 5,21 -RRB- = 0.75 , p > 0.05	15919
oneway ANOVA F -LRB- 5,21 -RRB- = 0.75 , p >	15919
oneway ANOVA F -LRB- 5,21 -RRB- = 0.75	15919
oneway ANOVA F -LRB- 5,21 -RRB-	15919
oneway ANOVA F	15919
5,21	15934
0.75	15940
p >	15946
p	15946
0.05	15948
the AT and 4WDT groups	15955
the AT	15955
4WDT groups	15966
higher levels of spinal tissue sparing	15988
higher levels	15988
spinal tissue sparing	16005
488.7 ± 101.1 ; 613.2 ± 77.1 , respectively	16028
488.7 ± 101.1 ; 613.2 ± 77.1	16028
488.7 ± 101.1	16028
488.7	16028
101.1	16034
613.2 ± 77.1	16041
613.2	16041
77.1	16047
their respective controls , the AC and 4WDC groups	16084
their respective controls	16084
the AC	16111
4WDC groups	16122
303.1 ± 77.3 ; 414.8 ± 96.4 , respectively	16135
303.1 ± 77.3 ; 414.8 ± 96.4	16135
303.1 ± 77.3	16135
303.1	16135
77.3	16141
414.8 ± 96.4	16147
414.8	16147
96.4	16153
The 2-week delayed transplantation of both lamina propria grafts	16174
The 2-week delayed transplantation	16174
both lamina propria grafts	16212
similar spinal tissue sparing levels -LRB- 450.9 ± 123.2 ; 478.6 ± 120.9 respectively -RRB- -LRB- Fig. 2A -RRB-	16256
similar spinal tissue sparing levels -LRB- 450.9 ± 123.2 ; 478.6 ± 120.9 respectively -RRB-	16256
similar spinal tissue sparing levels	16256
450.9 ± 123.2 ; 478.6 ± 120.9	16294
450.9 ± 123.2	16294
450.9	16294
123.2	16300
478.6 ± 120.9	16307
478.6	16307
120.9	16313
Fig. 2A	16334
The presence of sprouting axons	16344
The presence	16344
axons	16370
growth associated protein-43 -LRB- GAP-43 -RRB- immunoreactivity at the SCI site of the groups -LRB- AC -- 0.1 ± 0.0 ; AT -- 0.2 ± 0.0 ; 2WDC -- 0.1 ± 0.0 ; 2WDT -- 0.1 ± 0.0 ; 4WDC -- 0.1 ± 0.0 ; 4WDT -- 0.2 ± 0.0 -RRB-	16393
growth	16393
protein-43 -LRB- GAP-43 -RRB- immunoreactivity at the SCI site of the groups -LRB- AC -- 0.1 ± 0.0 ; AT -- 0.2 ± 0.0 ; 2WDC -- 0.1 ± 0.0 ; 2WDT -- 0.1 ± 0.0 ; 4WDC -- 0.1 ± 0.0 ; 4WDT -- 0.2 ± 0.0 -RRB-	16411
protein-43 -LRB- GAP-43 -RRB- immunoreactivity	16411
protein-43 -LRB- GAP-43 -RRB-	16411
protein-43	16411
GAP-43	16423
the SCI site of the groups -LRB- AC -- 0.1 ± 0.0 ; AT -- 0.2 ± 0.0 ; 2WDC -- 0.1 ± 0.0 ; 2WDT -- 0.1 ± 0.0 ; 4WDC -- 0.1 ± 0.0 ; 4WDT -- 0.2 ± 0.0 -RRB-	16451
the SCI site	16451
the groups -LRB- AC -- 0.1 ± 0.0 ; AT -- 0.2 ± 0.0 ; 2WDC -- 0.1 ± 0.0 ; 2WDT -- 0.1 ± 0.0 ; 4WDC -- 0.1 ± 0.0 ; 4WDT -- 0.2 ± 0.0 -RRB-	16467
the groups	16467
AC -- 0.1 ± 0.0 ; AT -- 0.2 ± 0.0 ; 2WDC -- 0.1 ± 0.0 ; 2WDT -- 0.1 ± 0.0 ; 4WDC -- 0.1 ± 0.0 ; 4WDT -- 0.2 ± 0.0	16479
AC	16479
0.1 ± 0.0 ; AT -- 0.2 ± 0.0 ; 2WDC -- 0.1 ± 0.0 ; 2WDT -- 0.1 ± 0.0 ; 4WDC -- 0.1 ± 0.0 ; 4WDT -- 0.2 ± 0.0	16482
0.1 ± 0.0	16482
0.1	16482
0.0	16486
AT -- 0.2 ± 0.0	16491
AT	16491
0.2 ± 0.0	16494
0.2	16494
0.0	16498
2WDC -- 0.1 ± 0.0	16503
2WDC -- 0.1	16503
0.0	16513
2WDT -- 0.1 ± 0.0	16518
2WDT -- 0.1	16518
0.0	16527
4WDC -- 0.1 ± 0.0	16532
4WDC -- 0.1	16532
0.0	16541
4WDT -- 0.2 ± 0.0	16546
4WDT -- 0.2	16546
0.0	16555
The optical densitometry for this protein	16561
The optical densitometry	16561
this protein	16590
no differences	16610
OLP transplanted groups with their respective RLP controls -LRB- one-way ANOVA F -LRB- 5,25 -RRB- = 0.64 , p > 0.05 -RRB- -LRB- Figs. 2B , C , D -RRB-	16664
OLP transplanted groups	16664
their respective RLP controls -LRB- one-way ANOVA F -LRB- 5,25 -RRB- = 0.64 , p > 0.05 -RRB- -LRB- Figs. 2B , C , D -RRB-	16693
their respective RLP controls -LRB- one-way ANOVA F -LRB- 5,25 -RRB- = 0.64 , p > 0.05 -RRB-	16693
their respective RLP controls	16693
one-way ANOVA F -LRB- 5,25 -RRB- = 0.64 , p > 0.05	16724
one-way ANOVA F -LRB- 5,25 -RRB- = 0.64 , p >	16724
one-way ANOVA F -LRB- 5,25 -RRB- = 0.64	16724
one-way ANOVA F -LRB- 5,25 -RRB-	16724
one-way ANOVA F	16724
5,25	16740
0.64	16746
p >	16752
p	16752
0.05	16754
Figs. 2B	16761
C	16771
D	16774
2.3	16778
Retrograde tracer	16783
cells	16809
Few fluorogold -LRB- FG -RRB-	16815
Few fluorogold	16815
FG	16831
positive neurons	16835
the brain areas of the animals that received OLP and RLP transplantation -LRB- Table 1 -RRB-	16866
the brain areas	16866
the animals that received OLP and RLP transplantation -LRB- Table 1 -RRB-	16885
the animals	16885
OLP and RLP transplantation	16911
Table 1	16940
The observed labeled cell bodies	16950
The	16950
cell bodies	16971
size	17002
clusters , as previously described by Vavrek et al. -LRB- 2007 -RRB-	17023
clusters	17023
Vavrek	17060
et al. -LRB- 2007 -RRB-	17067
et al.	17067
2007	17075
The primary and secondary motor cortices -LRB- M1/M2 -RRB-	17082
The primary and secondary motor cortices	17082
M1/M2	17124
neurons in any groups	17155
neurons	17155
any groups	17166
Only one animal , from the AC group ,	17178
Only one animal	17178
the AC group	17200
FG-positive neurons in the primary somatosensory cortex -LRB- S1 -RRB-	17231
FG-positive neurons	17231
the primary somatosensory cortex -LRB- S1 -RRB-	17254
the primary somatosensory cortex	17254
S1	17288
the brainstem	17296
animals from the AC group	17311
animals	17311
the AC group	17324
neurons in the spinal vestibular nucleus -LRB- SpVe -RRB- , lateral vestibular nucleus -LRB- LVe -RRB- , caudal and rostral pontine reticular nuclei -LRB- PnO/PnC -RRB-	17352
neurons	17352
the spinal vestibular nucleus -LRB- SpVe -RRB- , lateral vestibular nucleus -LRB- LVe -RRB- , caudal and rostral pontine reticular nuclei -LRB- PnO/PnC -RRB-	17363
the spinal vestibular nucleus -LRB- SpVe -RRB- , lateral vestibular nucleus -LRB- LVe -RRB- , caudal and rostral pontine reticular nuclei	17363
the spinal vestibular nucleus -LRB- SpVe -RRB- , lateral vestibular nucleus -LRB- LVe -RRB- , caudal and rostral pontine	17363
the spinal vestibular nucleus -LRB- SpVe -RRB-	17363
the spinal vestibular nucleus	17363
SpVe	17394
lateral vestibular nucleus -LRB- LVe -RRB-	17401
lateral vestibular nucleus	17401
LVe	17429
caudal and rostral pontine	17435
PnO/PnC	17480
animals	17493
the AT group	17506
FG-positive neurons	17529
the dorsal and ventral medullary reticular fields -LRB- MdD/MdV -RRB- , raphe nuclei -LRB- Ra -RRB- , SpVe , LVe and PnO/PnC nuclei	17552
the dorsal and ventral medullary reticular fields -LRB- MdD/MdV -RRB-	17552
the dorsal and ventral medullary reticular fields	17552
MdD/MdV	17603
raphe nuclei -LRB- Ra -RRB-	17613
raphe nuclei	17613
Ra	17627
SpVe , LVe and PnO/PnC nuclei	17632
the 2-week delayed groups	17665
FG-labeled neurons	17692
the LVe nuclei of the 2WDC group	17728
the LVe nuclei	17728
the 2WDC group	17746
the PnO/PnC of the 2WDT group	17768
the PnO/PnC	17768
the 2WDT group	17783
The 4WDC group	17799
few FG-positive neurons	17824
the LVe nuclei	17851
no labeled neurons	17873
any studied areas of the 4WDT group -LRB- Table 1 -RRB-	17909
any	17909
areas of the 4WDT group -LRB- Table 1 -RRB-	17921
areas	17921
the 4WDT group -LRB- Table 1 -RRB-	17930
the 4WDT group	17930
Table 1	17946
2.4	17956
Serotonin -LRB- 5-HT -RRB- and calcitonin gene-related peptide -LRB- CGRP -RRB-	17961
Serotonin -LRB- 5-HT -RRB-	17961
Serotonin	17961
5-HT	17972
calcitonin gene-related peptide -LRB- CGRP -RRB-	17982
calcitonin gene-related peptide	17982
CGRP	18015
pattern fibers in caudal , rostral and lesion areas Animals transplanted with both types of lamina propria had most evident 5-HT immunostained fibers in the rostral stump of longitudinal spinal cord sections	18021
pattern fibers	18021
caudal , rostral and lesion areas Animals	18039
transplanted with both types of lamina propria	18080
transplanted	18080
both types of lamina propria	18098
both types	18098
lamina propria	18112
most evident 5-HT immunostained fibers	18131
the rostral stump of longitudinal spinal cord sections	18173
the rostral stump	18173
longitudinal spinal cord sections	18194
AC -- 0.9 ± 0.2 ; AT -- 1.0 ± 0.5 ; 2WDC -- 0.5 ± 0.3 ; 2WDT -- 0.4 ± 0.0 ; 4WDC -- 0.7 ± 0.2 ; 4WDT -- 0.6 ± 0.0	18229
AC	18229
0.9 ± 0.2 ; AT -- 1.0 ± 0.5 ; 2WDC -- 0.5 ± 0.3 ; 2WDT -- 0.4 ± 0.0 ; 4WDC -- 0.7 ± 0.2 ; 4WDT -- 0.6 ± 0.0	18232
0.9 ± 0.2	18232
0.9	18232
0.2	18236
AT -- 1.0 ± 0.5	18241
AT	18241
1.0 ± 0.5	18245
1.0	18245
0.5	18249
2WDC -- 0.5 ± 0.3	18254
2WDC -- 0.5	18254
± 0.3	18262
2WDT -- 0.4 ± 0.0	18268
2WDT -- 0.4	18268
0.0	18277
4WDC -- 0.7 ± 0.2	18282
4WDC -- 0.7	18282
0.2	18291
4WDT -- 0.6 ± 0.0	18296
4WDT -- 0.6	18296
0.0	18305
A GFAP negative region	18311
the injured area	18345
the spinal cord	18365
most animals	18389
5-HT fibers	18403
the vicinity of the lesion border -LRB- AC -- 0.00 ± 0.0 ; AT -- 0.01 ± 0.0 ; 2WDC -- 0.00 ± 0.0 ; 2WDT -- 0.01 ± 0.0 ; 4WDC -- 0.03 ± 0.0 ; 4WDT -- 0.02 ± 0.0 -RRB-	18437
the vicinity	18437
the lesion border -LRB- AC -- 0.00 ± 0.0 ; AT -- 0.01 ± 0.0 ; 2WDC -- 0.00 ± 0.0 ; 2WDT -- 0.01 ± 0.0 ; 4WDC -- 0.03 ± 0.0 ; 4WDT -- 0.02 ± 0.0 -RRB-	18453
the lesion border	18453
AC -- 0.00 ± 0.0 ; AT -- 0.01 ± 0.0 ; 2WDC -- 0.00 ± 0.0 ; 2WDT -- 0.01 ± 0.0 ; 4WDC -- 0.03 ± 0.0 ; 4WDT -- 0.02 ± 0.0	18472
AC	18472
0.00 ± 0.0 ; AT -- 0.01 ± 0.0 ; 2WDC -- 0.00 ± 0.0 ; 2WDT -- 0.01 ± 0.0 ; 4WDC -- 0.03 ± 0.0 ; 4WDT -- 0.02 ± 0.0	18476
0.00 ± 0.0	18476
0.00	18476
0.0	18481
AT -- 0.01 ± 0.0	18486
AT	18486
0.01 ± 0.0	18489
0.01	18489
0.0	18494
2WDC -- 0.00 ± 0.0	18499
2WDC -- 0.00	18499
0.0	18509
2WDT -- 0.01 ± 0.0	18514
2WDT -- 0.01	18514
0.0	18524
4WDC -- 0.03 ± 0.0	18529
4WDC -- 0.03	18529
0.0	18539
4WDT -- 0.02 ± 0.0	18544
4WDT -- 0.02	18544
0.0	18554
the majority of slices analyzed	18573
the majority	18573
slices analyzed	18589
slices	18589
no 5-HT labeled axons	18606
no 5-HT	18606
axons	18622
the caudal stump -LRB- AC -- 0.00 ± 0.0 ; AT -- 0.00 ± 0.0 ; 2WDC -- 0.01 ± 0.0 ; 2WDT -- 0.01 ± 0.0 ; 4WDC -- 0.00 ± 0.0 ; 4WDT -- 0.00 ± 0.0 -RRB- -LRB- Figs. 3 , 4 -RRB-	18642
the caudal stump -LRB- AC -- 0.00 ± 0.0 ; AT -- 0.00 ± 0.0 ; 2WDC -- 0.01 ± 0.0 ; 2WDT -- 0.01 ± 0.0 ; 4WDC -- 0.00 ± 0.0 ; 4WDT -- 0.00 ± 0.0 -RRB-	18642
the caudal stump	18642
AC -- 0.00 ± 0.0 ; AT -- 0.00 ± 0.0 ; 2WDC -- 0.01 ± 0.0 ; 2WDT -- 0.01 ± 0.0 ; 4WDC -- 0.00 ± 0.0 ; 4WDT -- 0.00 ± 0.0	18660
AC	18660
0.00 ± 0.0 ; AT -- 0.00 ± 0.0 ; 2WDC -- 0.01 ± 0.0 ; 2WDT -- 0.01 ± 0.0 ; 4WDC -- 0.00 ± 0.0 ; 4WDT -- 0.00 ± 0.0	18663
0.00 ± 0.0	18663
0.00	18663
0.0	18668
AT -- 0.00 ± 0.0	18673
AT	18673
0.00 ± 0.0	18676
0.00	18676
0.0	18681
2WDC -- 0.01 ± 0.0	18686
2WDC -- 0.01	18686
0.0	18696
2WDT -- 0.01 ± 0.0	18701
2WDT -- 0.01	18701
0.0	18711
4WDC -- 0.00 ± 0.0	18716
4WDC -- 0.00	18716
0.0	18726
4WDT -- 0.00 ± 0.0	18731
4WDT -- 0.00	18731
0.0	18741
Figs. 3	18747
4	18756
No differences	18760
the 5-HT immunoreactivity of the rostral , lesion and caudal regions of spinal cord when all groups were compared -LRB- Kruskal -- Wallis p = 0.37 ; p = 0.73 ; p = 0.34 , respectively -RRB- -LRB- Fig. 6 -RRB-	18792
the 5-HT immunoreactivity	18792
the rostral , lesion and caudal regions of spinal cord when all groups were compared -LRB- Kruskal -- Wallis p = 0.37 ; p = 0.73 ; p = 0.34 , respectively -RRB- -LRB- Fig. 6 -RRB-	18821
the rostral , lesion and caudal regions	18821
spinal cord when all groups were compared -LRB- Kruskal -- Wallis p = 0.37 ; p = 0.73 ; p = 0.34 , respectively -RRB-	18863
spinal cord	18863
all groups	18880
Kruskal	18906
Wallis p = 0.37 ; p = 0.73 ; p = 0.34 , respectively	18914
Wallis	18914
p = 0.37 ; p = 0.73 ; p = 0.34 , respectively	18921
p = 0.37	18921
p	18921
0.37	18923
p = 0.73	18929
p	18929
0.73	18931
p = 0.34 , respectively	18937
p	18937
= 0.34	18938
Fig. 6	18960
sensory fibers immunostained by CGRP	18992
sensory fibers	18992
CGRP	19024
the caudal stump of the experimental groups -LRB- AC -- 1.27 ± 0.3 ; AT -- 1.08 ± 0.3 ; 2WDC -- 1.42 ± 0.6 ; 2WDT -- 1.42 ± 0.8 ; 4WDC -- 0.87 ± 0.2 ; 4WDT -- 1.10 ± 0.2 -RRB-	19046
the caudal stump	19046
the experimental groups -LRB- AC -- 1.27 ± 0.3 ; AT -- 1.08 ± 0.3 ; 2WDC -- 1.42 ± 0.6 ; 2WDT -- 1.42 ± 0.8 ; 4WDC -- 0.87 ± 0.2 ; 4WDT -- 1.10 ± 0.2 -RRB-	19066
the experimental groups	19066
AC	19091
1.27 ± 0.3 ; AT -- 1.08 ± 0.3 ; 2WDC -- 1.42 ± 0.6 ; 2WDT -- 1.42 ± 0.8 ; 4WDC -- 0.87 ± 0.2 ; 4WDT -- 1.10 ± 0.2	19094
1.27 ±	19094
0.3 ; AT -- 1.08 ± 0.3 ; 2WDC -- 1.42 ± 0.6 ; 2WDT -- 1.42 ± 0.8 ; 4WDC -- 0.87 ± 0.2 ; 4WDT -- 1.10 ± 0.2	19099
0.3 ; AT	19099
0.3	19099
AT	19104
1.08 ± 0.3 ; 2WDC	19107
1.08 ±	19107
0.3 ; 2WDC	19112
1.42 ± 0.6 ; 2WDT	19122
1.42 ±	19122
0.6 ; 2WDT	19127
1.42 ± 0.8	19138
1.42 ±	19138
0.8	19143
4WDC -- 0.87 ± 0.2	19148
4WDC -- 0.87	19148
0.2	19158
4WDT -- 1.10 ± 0.2	19163
4WDT -- 1.10	19163
0.2	19173
There	19179
considerable levels of CGRP fibers	19190
considerable levels	19190
CGRP fibers	19213
the lesion region -LRB- AC -- 1.71 ± 0.4 ; AT -- 1.37 ± 0.3 ; 2WDC -- 0.88 ± 0.2 ; 2WDT -- 1.19 ± 0.1 ; 4WDC -- 0.85 ± 0.2 ; 4WDT -- 1.75 ± 0.5 -RRB-	19228
the lesion region	19228
AC	19247
1.71 ± 0.4 ; AT -- 1.37 ± 0.3 ; 2WDC -- 0.88 ± 0.2 ; 2WDT -- 1.19 ± 0.1 ; 4WDC -- 0.85 ± 0.2 ; 4WDT -- 1.75 ± 0.5	19251
1.71 ±	19251
0.4 ; AT -- 1.37 ± 0.3 ; 2WDC -- 0.88 ± 0.2 ; 2WDT -- 1.19 ± 0.1 ; 4WDC -- 0.85 ± 0.2 ; 4WDT -- 1.75 ± 0.5	19256
0.4 ; AT	19256
0.4	19256
AT	19261
1.37 ± 0.3	19264
1.37 ±	19264
0.3	19269
2WDC -- 0.88 ± 0.2	19274
2WDC -- 0.88	19274
0.2	19284
2WDT -- 1.19 ± 0.1	19289
2WDT -- 1.19	19289
0.1	19299
4WDC -- 0.85 ± 0.2	19304
4WDC -- 0.85	19304
0.2	19314
4WDT -- 1.75 ± 0.5	19319
4WDT -- 1.75	19319
0.5	19329
both OLP and RLP transplantation	19348
OLP	19353
RLP transplantation	19361
the growth/sprouting of CGRP fibers	19392
the growth/sprouting	19392
CGRP fibers	19416
animals submitted to SCI	19431
animals	19431
SCI	19452
the rostral stump	19460
CGRP immunoreactive fibers	19479
all groups	19528
the AT and 2WDC groups -LRB- AC -- 1.56 ± 0.9 ; AT -- 3.58 ± 2.1 ; 2WDC -- 4.10 ± 3.0 ; 2WDT -- 1.40 ± 0.6 ; 4WDC -- 1.79 ± 0.9 ; 4WDT -- 1.29 ± 0.5 -RRB- -LRB- Figs. 3 , 5 -RRB-	19560
the AT and 2WDC groups -LRB- AC -- 1.56 ± 0.9 ; AT -- 3.58 ± 2.1 ; 2WDC -- 4.10 ± 3.0 ; 2WDT -- 1.40 ± 0.6 ; 4WDC -- 1.79 ± 0.9 ; 4WDT -- 1.29 ± 0.5 -RRB-	19560
the AT and 2WDC groups	19560
the AT	19560
2WDC groups	19571
AC -- 1.56 ± 0.9 ; AT -- 3.58 ± 2.1 ; 2WDC -- 4.10 ± 3.0 ; 2WDT -- 1.40 ± 0.6 ; 4WDC -- 1.79 ± 0.9 ; 4WDT -- 1.29 ± 0.5	19584
AC	19584
1.56 ± 0.9 ; AT -- 3.58 ± 2.1 ; 2WDC -- 4.10 ± 3.0 ; 2WDT -- 1.40 ± 0.6 ; 4WDC -- 1.79 ± 0.9 ; 4WDT -- 1.29 ± 0.5	19588
1.56 ± 0.9	19588
1.56	19588
0.9	19593
AT -- 3.58 ± 2.1	19598
AT	19598
3.58 ± 2.1	19601
3.58 ±	19601
2.1	19606
2WDC -- 4.10 ± 3.0	19611
2WDC -- 4.10	19611
3.0	19621
2WDT -- 1.40 ± 0.6	19626
2WDT -- 1.40	19626
± 0.6	19635
4WDC -- 1.79 ± 0.9	19641
4WDC -- 1.79	19641
0.9	19651
4WDT -- 1.29 ± 0.5	19656
4WDT -- 1.29	19656
0.5	19666
Figs. 3	19672
5	19681
No differences in the rostral , lesion and caudal regions of the spinal cord	19685
No differences	19685
the rostral , lesion and caudal regions of the spinal cord	19703
the rostral , lesion and caudal regions	19703
the spinal cord	19745
the groups -LRB- Kruskal -- Wallis p = 0.97 ; p = 0.25 ; p = 0.90 , respectively -RRB- -LRB- Fig. 6 -RRB-	19785
the groups -LRB- Kruskal -- Wallis p = 0.97 ; p = 0.25 ; p = 0.90 , respectively -RRB-	19785
the groups	19785
Kruskal	19797
Wallis p = 0.97 ; p = 0.25 ; p = 0.90 , respectively	19805
Wallis	19805
p = 0.97 ; p = 0.25 ; p = 0.90 , respectively	19812
p = 0.97	19812
p	19812
0.97	19814
p = 0.25	19820
p	19820
0.25	19822
p = 0.90 , respectively	19828
p	19828
= 0.90	19829
Fig. 6	19851
Discussion The hindlimb motor recovery and axonal growth-promoting effects of OECs , OLP and olfactory mucosa	19864
Discussion The hindlimb motor recovery	19864
Discussion	19864
The hindlimb motor recovery	19875
axonal growth-promoting effects of OECs , OLP and olfactory mucosa	19907
axonal growth-promoting effects	19907
OECs , OLP and olfactory mucosa	19942
OECs	19942
OLP	19948
olfactory mucosa	19956
different models of spinal cord lesions -LRB- see Table 2 -RRB-	19994
different models	19994
spinal cord lesions	20014
Table 2	20039
the present study	20052
we	20071
the restorative efficiency of OLP and RLP transplants , in three different therapeutic windows -LRB- acutely , 2-week and 4-week delayed -RRB-	20105
the restorative efficiency	20105
OLP and RLP transplants , in three different therapeutic windows -LRB- acutely , 2-week and 4-week delayed -RRB-	20135
OLP	20135
RLP transplants , in three different therapeutic windows -LRB- acutely , 2-week and 4-week delayed	20143
RLP transplants	20143
three different therapeutic windows -LRB- acutely , 2-week and 4-week delayed	20163
three different therapeutic windows	20163
2-week	20209
a complete thoracic spinal cord transection in adult rats	20243
a complete thoracic spinal cord transection	20243
adult rats	20290
the twelfth week after transplantation	20305
the twelfth week	20305
transplantation	20328
animals with OLP or RLP	20345
animals	20345
OLP or RLP	20358
a discrete and similar hindlimb motor improvement	20376
All transplants	20427
comparable results	20452
spinal cord tissue sparing	20475
GFAP and GAP-43 immunohistochemistry	20533
Acute transplantation of OLP and RLP	20571
Acute transplantation	20571
OLP and RLP	20596
some limited supraspinal axonal regeneration	20624
the presence of cells stained by retrograde tracing in brainstem nuclei	20686
the presence	20686
cells stained by retrograde tracing in brainstem nuclei	20702
cells	20702
brainstem nuclei	20741
retrogradely labeled cells in cortical areas	20768
retrogradely labeled cells	20768
cortical areas	20798
acute RLP transplantation	20842
A larger number of 5-HT positive fibers	20869
A larger number	20869
5-HT positive fibers	20888
the cranial stump of the OLP and RLP groups	20923
the cranial stump	20923
the OLP and RLP groups	20944
the lesion and caudal regions analyzed	20979
the lesion and caudal regions	20979
CGRP fibers	21019
considerable number	21047
the SCI site	21070
transplantation types	21091
the mechanisms underlying the regenerative properties of OECs in the SCI site	21123
the mechanisms	21123
the regenerative properties of OECs in the SCI site	21149
the regenerative properties	21149
OECs in the SCI site	21180
OECs	21180
the SCI site	21188
reduction of glial scarring -LRB- Lu et al. , 2006 -RRB- , facilitation of axon re-entry into the host -- graft interface -LRB- Li et al. , 2005 -RRB- , reduction of proteoglycan expression -LRB- García-Alías et al. , 2004 -RRB- , angiogenesis -LRB- Richter et al. , 2005 -RRB- , remyelination -LRB- Sasaki et al. , 2006 -RRB- and growth-factors release -LRB- Lipson et al. , 2003 -RRB-	21232
reduction	21232
glial scarring -LRB- Lu et al. , 2006 -RRB- , facilitation of axon re-entry into the host -- graft interface -LRB- Li et al. , 2005 -RRB- , reduction of proteoglycan expression -LRB- García-Alías et al. , 2004 -RRB- , angiogenesis -LRB- Richter et al. , 2005 -RRB- , remyelination -LRB- Sasaki et al. , 2006 -RRB- and growth-factors release -LRB- Lipson et al. , 2003 -RRB-	21245
glial scarring -LRB- Lu et al. , 2006 -RRB-	21245
glial scarring	21245
Lu	21261
et al. , 2006	21264
et al.	21264
2006	21272
facilitation of axon re-entry into the host -- graft interface -LRB- Li et al. , 2005 -RRB- , reduction of proteoglycan expression -LRB- García-Alías et al. , 2004 -RRB- , angiogenesis -LRB- Richter et al. , 2005 -RRB- , remyelination -LRB- Sasaki et al. , 2006 -RRB- and growth-factors release -LRB- Lipson et al. , 2003 -RRB-	21279
facilitation of axon re-entry into the host	21279
facilitation	21279
axon re-entry into the host	21295
axon re-entry	21295
the host	21314
graft interface -LRB- Li et al. , 2005 -RRB- , reduction of proteoglycan expression -LRB- García-Alías et al. , 2004 -RRB- , angiogenesis -LRB- Richter et al. , 2005 -RRB- , remyelination -LRB- Sasaki et al. , 2006 -RRB- and growth-factors release -LRB- Lipson et al. , 2003 -RRB-	21323
graft interface -LRB- Li et al. , 2005 -RRB-	21323
graft interface	21323
Li	21340
et al. , 2005	21343
et al.	21343
2005	21351
reduction of proteoglycan expression -LRB- García-Alías et al. , 2004 -RRB-	21358
reduction	21358
proteoglycan expression	21371
García-Alías	21396
et al. , 2004	21409
et al.	21409
2004	21417
angiogenesis -LRB- Richter et al. , 2005 -RRB-	21424
angiogenesis	21424
Richter	21438
et al. , 2005	21446
et al.	21446
2005	21454
remyelination -LRB- Sasaki et al. , 2006 -RRB-	21461
remyelination	21461
Sasaki	21476
et al. , 2006	21483
et al.	21483
2006	21491
growth-factors release -LRB- Lipson et al. , 2003 -RRB-	21501
growth-factors release	21501
Lipson	21525
et al. , 2003	21532
et al.	21532
2003	21540
the main benefits of this cell transplantation -LRB- Tetzlaff et al. , 2011 -RRB-	21561
the main benefits	21561
this cell transplantation -LRB- Tetzlaff et al. , 2011 -RRB-	21582
this cell transplantation	21582
Tetzlaff	21609
et al. , 2011	21618
et al.	21618
2011	21626
We	21633
the presence of OECs in the lamina propria	21656
the presence	21656
OECs in the lamina propria	21672
OECs	21672
the lamina propria	21680
the transection site	21728
the limitations of our study	21754
the limitations	21754
our study	21773
the lack of the OECs quantification and the inability to investigate the possible migratory properties of these cells after transplantation	21788
the lack of the OECs quantification	21788
the lack	21788
the OECs quantification	21800
the inability to investigate the possible migratory properties of these cells after transplantation	21828
the possible migratory properties of these cells	21857
the possible migratory properties	21857
these cells	21894
transplantation	21912
some aspects of OECs behavior after transplantation	21943
some aspects	21943
OECs behavior after transplantation	21959
OECs behavior	21959
transplantation	21979
an olfactory nerve injury	22031
OECs	22058
the lesion site forming a conduit that can guide regenerating nerve axons , analogously to Schwann cells after a peripheral nerve injury -LRB- Li et al. , 2005 ; Williams et al. , 2004 -RRB-	22086
the lesion site	22086
a conduit that can guide regenerating nerve axons	22110
a conduit	22110
nerve axons	22148
Schwann cells	22176
a peripheral nerve injury -LRB- Li et al. , 2005 ; Williams et al. , 2004 -RRB-	22196
a peripheral nerve injury	22196
Li	22223
et al. , 2005 ; Williams et al. , 2004	22226
et al.	22226
2005 ; Williams et al.	22234
2005	22234
Williams et al.	22240
Williams	22240
et al.	22249
2004	22257
a cervical spinal cord injury model	22270
Lu et al. -LRB- 2006 -RRB-	22307
Lu et al.	22307
Lu	22307
et al.	22310
2006	22318
any unique migratory properties of OECs	22346
any unique migratory properties	22346
OECs	22381
these cells	22403
the injection site	22450
active migration	22478
the other hand	22499
Richter et al. -LRB- 2005 -RRB-	22515
Richter et al.	22515
Richter	22515
et al.	22523
2005	22531
a superior migratory ability of OECs derived from lamina propria when	22544
a superior migratory ability	22544
OECs derived from lamina propria when	22576
OECs	22576
lamina propria	22594
OECs derived from OB after crush of spinal cord dorsolateral funiculus at the C3 -- C4 level	22626
OECs	22626
OB	22644
crush of spinal cord dorsolateral funiculus	22653
crush	22653
spinal cord dorsolateral funiculus	22662
the C3 -- C4 level	22700
the C3	22700
C4 level	22707
the migratory capacity of these cells after transplantation into different injury sites	22723
the migratory capacity	22723
these cells after transplantation into different injury sites	22749
these cells	22749
transplantation into different injury sites	22767
transplantation	22767
different injury sites	22788
OLP transplants	22835
the dual advantage of providing a physical bridge that couldmechanically favor axonal sprouting aswell as being a reservoir of OECs -LRB- Lu et al. , 2002 -RRB-	22856
the dual advantage	22856
a physical bridge that couldmechanically favor axonal sprouting aswell as being a reservoir of OECs -LRB- Lu et al. , 2002 -RRB-	22888
a physical bridge	22888
a reservoir of OECs -LRB- Lu et al. , 2002 -RRB-	22968
a reservoir	22968
OECs -LRB- Lu et al. , 2002 -RRB-	22983
OECs	22983
Lu	22989
et al. , 2002	22992
et al.	22992
2002	23000
RLP	23007
the same bridging function and shares many of the cell types with OLP -LRB- olfactory nerve bundles , trigeminal nerve fibers , Schwann cells , endothelium , interstitial fibroblasts and tissue resident immune cells -RRB- -LRB- Mackay-Sim and St John , 2011 -RRB-	23020
the same bridging function	23020
shares many of the cell types with OLP -LRB- olfactory nerve bundles , trigeminal nerve fibers , Schwann cells , endothelium , interstitial fibroblasts and tissue resident immune cells -RRB- -LRB- Mackay-Sim and St John , 2011 -RRB-	23051
shares many	23051
the cell types with OLP -LRB- olfactory nerve bundles , trigeminal nerve fibers , Schwann cells , endothelium , interstitial fibroblasts and tissue resident immune cells -RRB- -LRB- Mackay-Sim and St John , 2011 -RRB-	23066
the cell types	23066
OLP -LRB- olfactory nerve bundles , trigeminal nerve fibers , Schwann cells , endothelium , interstitial fibroblasts and tissue resident immune cells -RRB- -LRB- Mackay-Sim and St John , 2011 -RRB-	23086
OLP -LRB- olfactory nerve bundles , trigeminal nerve fibers , Schwann cells , endothelium , interstitial fibroblasts and tissue resident immune cells -RRB-	23086
OLP	23086
olfactory nerve bundles , trigeminal nerve fibers , Schwann cells , endothelium , interstitial fibroblasts and tissue resident immune cells	23091
olfactory nerve bundles	23091
trigeminal nerve fibers	23116
Schwann cells	23141
endothelium	23156
interstitial fibroblasts	23169
tissue resident immune cells	23198
tissue	23198
resident immune cells	23205
Mackay-Sim and St John , 2011	23229
Mackay-Sim and St John	23229
2011	23253
These shared cells present in RLP	23260
These shared cells	23260
RLP	23290
the hindlimb motor improvement and the CGRP regeneration observed at the lesion site -LRB- Lindsay et al. , 2010 -RRB-	23324
the hindlimb motor improvement	23324
the CGRP regeneration observed at the lesion site -LRB- Lindsay et al. , 2010 -RRB-	23359
the CGRP regeneration	23359
the lesion site -LRB- Lindsay et al. , 2010 -RRB-	23393
the lesion site	23393
Lindsay	23410
et al. , 2010	23418
et al.	23418
2010	23426
the other hand	23436
the restoration of a cell continuum alone within the spinal cord	23452
the restoration	23452
a cell continuum alone within the spinal cord	23471
a cell continuum alone	23471
the spinal cord	23501
the results found with both transplant types	23549
the results	23549
both transplant types	23572
this latter hypothesis	23608
animals in which 4 mm were removed from spinal cord and with a matrigel only-bridge	23632
animals	23632
4 mm	23649
spinal cord	23671
a matrigel only-bridge	23692
BBB scores	23722
those observed in the RLP groups	23747
those	23747
the RLP groups	23765
the animals transplanted with matrigel	23784
the animals	23784
matrigel	23814
myelinated axons	23824
the injury site	23859
5-HT positive fibers crossing the lesion and penetrating the caudal stump -LRB- Fouad et al. , 2005 -RRB-	23881
5-HT positive fibers	23881
the lesion	23911
the caudal stump -LRB- Fouad et al. , 2005 -RRB-	23938
the caudal stump	23938
Fouad	23956
et al. , 2005	23962
et al.	23962
2005	23970
another similar study	23980
alginate-based capillary gels	24003
transection of the dorsal column	24053
transection	24053
the dorsal column	24068
the C3 level	24089
a robust growth of coerulospinal projections and GAP-43 positive fibers	24114
a robust growth	24114
coerulospinal projections and GAP-43 positive fibers	24133
coerulospinal projections	24133
GAP-43 positive fibers	24163
the hydrogel -LRB- Prang et al. , 2006 -RRB-	24203
the hydrogel	24203
Prang	24217
et al. , 2006	24223
et al.	24223
2006	24231
animals	24247
spinal cord transection and injections of culture medium only -LRB- without any bridge at the lesion -RRB- , also obtained BBB scores that were very close to those observed with our OLP/RLP grafts	24268
spinal cord transection	24268
injections of culture	24296
injections	24296
culture	24310
medium only -LRB- without any bridge at the lesion -RRB-	24318
medium only	24318
any bridge at the lesion	24339
any bridge	24339
the lesion	24353
BBB scores that were very close to those observed with our OLP/RLP grafts	24380
BBB scores	24380
those observed with our OLP/RLP grafts	24415
those	24415
our OLP/RLP grafts	24435
Many GAP-43-immunoreactive axons	24455
the stumps of these culture-medium-injected group	24502
the stumps	24502
these culture-medium-injected group	24516
some CGRP-positive axons	24556
the lesion epicenter -LRB- López-Vales et al. , 2006 -RRB-	24589
the lesion epicenter	24589
López-Vales	24611
et al. , 2006	24623
et al.	24623
2006	24631
the present study	24641
a lesiononly control group	24660
control group	24673
order	24707
the use of a large number of animals	24722
the use	24722
a large number of animals	24733
a large number	24733
animals	24751
animals without any type of transplantation	24770
animals	24770
any type of transplantation	24786
any type	24786
transplantation	24798
the immune responses	24832
the other groups submitted to heterologous tissue transplantation	24864
the other groups	24864
heterologous tissue transplantation	24894
More studies	24931
comparable outcomes reported in this study	24975
comparable outcomes	24975
this study	25007
either untreated or matrigel-only bridge groups	25036
the possible positive effects exerted by cells other than OECs present in the RLP after spinal cord transection	25107
the possible positive effects	25107
cells other than OECs present in the RLP	25148
cells	25148
OECs present in the RLP	25165
OECs	25165
the RLP	25181
spinal cord transection	25195
Previous studies	25220
the importance of an appropriate post-injury period for repair	25253
the importance	25253
an appropriate post-injury period for repair	25271
an appropriate post-injury period	25271
repair	25309
SCI -LRB- Schiwy et al. , 2009 ; Takami et al. , 2002a -RRB-	25322
SCI	25322
Schiwy	25327
et al. , 2009 ; Takami et al. , 2002a	25334
et al.	25334
2009 ; Takami et al.	25342
2009	25342
Takami et al.	25348
Takami	25348
et al.	25355
2002a	25363
Most experimental studies	25371
OECs or tissue transplants acutely -LRB- Guest et al. , 2008 ; Kubasak et al. , 2008 ; Lu et al. , 2001 ; Ramón-Cueto and Avila , 1998 ; Ramón-Cueto et al. , 2000 -RRB-	25412
OECs or tissue transplants acutely	25412
OECs or tissue transplants	25412
Guest et al. , 2008 ; Kubasak et al. , 2008 ; Lu et al. , 2001 ; Ramón-Cueto and Avila , 1998 ; Ramón-Cueto et al. , 2000	25448
Guest	25448
et al. , 2008 ; Kubasak et al. , 2008 ; Lu et al. , 2001 ; Ramón-Cueto and Avila , 1998 ; Ramón-Cueto et al. , 2000	25454
et al. , 2008	25454
et al.	25454
2008	25462
Kubasak et al. , 2008	25468
Kubasak	25468
et al. , 2008	25476
et al.	25476
2008	25484
Lu et al. , 2001	25490
Lu	25490
et al. , 2001	25493
et al.	25493
2001	25501
Ramón-Cueto and Avila , 1998	25507
Ramón-Cueto and Avila	25507
1998	25530
Ramón-Cueto et al. , 2000	25536
Ramón-Cueto	25536
et al. , 2000	25548
et al.	25548
2000	25556
transplantation of purified OECs or lamina propria after SCI in humans	25572
transplantation	25572
OECs or lamina propria	25600
SCI	25629
humans	25636
Tetzlaff et al. , 2011	25669
Tetzlaff	25669
et al.	25678
2011	25686
The release of cytotoxic metabolites	25693
The release	25693
cytotoxic metabolites	25708
hemorrhage	25743
inflammation	25762
more acute interventions	25797
this procedure	25827
the transplanted cells at an intermediate stage -LRB- Deumens et al. , 2006 ; Martin et al. , 1996 -RRB-	25862
the transplanted cells	25862
an intermediate stage -LRB- Deumens et al. , 2006 ; Martin et al. , 1996 -RRB-	25888
an intermediate stage	25888
Deumens	25911
et al. , 2006 ; Martin et al. , 1996	25919
et al.	25919
2006 ; Martin et al.	25927
2006	25927
Martin et al.	25933
Martin	25933
et al.	25940
1996	25948
Lu et al. -LRB- 2001 , 2002 -RRB-	25955
Lu et al.	25955
Lu	25955
et al.	25958
2001	25966
2002	25972
a great improvement	25985
hindlimb motor function , spinal reflex	26008
hindlimb motor function	26008
spinal reflex	26033
regeneration of raphespinal fibers	26060
regeneration	26060
raphespinal fibers	26076
OLP transplantation	26100
4 weeks	26135
spinal cord transection	26149
the other hand	26177
Steward et al. -LRB- 2006 -RRB-	26193
Steward et al.	26193
Steward	26193
et al.	26201
2006	26209
evidence of functional recovery	26230
evidence	26230
functional recovery	26242
only limited regeneration of raphespinal axons	26273
only limited regeneration	26273
raphespinal axons	26302
spinal cord transection and 4-week delayed OLP transplantation	26326
spinal cord transection	26326
4-week delayed OLP transplantation	26354
our study	26393
functional recovery , tissue sparing and axon sprouting/regeneration outcomes	26404
recovery , tissue sparing and axon	26415
recovery	26415
tissue sparing	26425
axon	26444
animals	26505
OLP or RLP grafts , uninfluenced by the different transplantation times -LRB- acute , 2 weeks or 4 weeks post-injury -RRB-	26518
OLP or RLP grafts	26518
uninfluenced by the different transplantation times -LRB- acute , 2 weeks or 4 weeks post-injury -RRB-	26537
uninfluenced by the different transplantation times	26537
the different transplantation	26553
acute , 2 weeks or 4 weeks post-injury	26590
acute	26590
2 weeks	26597
4 weeks post-injury	26608
Raphespinal axons	26630
the lesion border	26671
CGRP fibers	26694
the center of the lesion	26722
the center	26722
the lesion	26736
both types of transplants	26753
both types	26753
transplants	26767
the optimal time-window for cellular or tissue transplantation	26786
the optimal time-window	26786
cellular or tissue transplantation	26814
cellular	26814
tissue transplantation	26826
this parameter	26882
the effects obtained from the grafts	26920
the effects	26920
the grafts	26946
addition	26961
CGRP axon regeneration	26974
nociception transmission	27015
interventions that favor axonal regeneration after SCI	27041
interventions	27041
axonal regeneration	27066
SCI	27092
appropriate rather than inappropriate connections	27130
Richter et al. , 2005	27194
Richter	27194
et al.	27202
2005	27210
current controversy in animal studies	27225
current controversy	27225
animal studies	27248
clinical trials using cultured OECs from lamina propria or olfactory mucosa grafts	27264
clinical trials	27264
OECs	27295
lamina propria or olfactory mucosa grafts	27305
chronically injured humans -LRB- Chhabra et al. , 2009 ; Féron et al. , 2005 ; Lima et al. , 2006 , 2010 ; Mackay-Sim et al. , 2008 -RRB-	27365
chronically injured humans	27365
Chhabra et al. , 2009 ; Féron et al. , 2005 ; Lima et al. , 2006 , 2010 ; Mackay-Sim et al. , 2008	27393
Chhabra	27393
et al. , 2009 ; Féron et al. , 2005 ; Lima et al. , 2006 , 2010 ; Mackay-Sim et al. , 2008	27401
et al. , 2009	27401
et al.	27401
2009	27409
Féron et al. , 2005	27415
Féron	27415
et al. , 2005	27421
et al.	27421
2005	27429
Lima et al. , 2006 , 2010	27435
Lima	27435
et al. , 2006 , 2010	27440
et al.	27440
2006	27448
2010	27454
Mackay-Sim et al. , 2008	27460
Mackay-Sim	27460
et al. , 2008	27471
et al.	27471
2008	27479
There	27486
divergence regarding the functional results	27501
divergence	27501
the functional results	27522
the procedures used in some of these studies	27560
the procedures	27560
some of these studies	27583
some	27583
these studies	27591
formal clinical trial protocols -LRB- Mackay-Sim and St John , 2011 -RRB-	27640
formal clinical trial protocols	27640
Mackay-Sim and St John , 2011	27673
Mackay-Sim and St John ,	27673
2011	27697
3.1	27705
Conclusions Acute , 2-week or 4-week delayed OLP and RLP transplantation	27710
Conclusions Acute , 2-week or 4-week	27710
Conclusions	27710
OLP and RLP transplantation	27754
a discrete functional recovery	27791
time and comparable CGRP fiber sprouting in the lesion site	27827
time and comparable CGRP fiber	27827
the lesion site	27871
regeneration of raphespinal descendent fibers	27910
regeneration	27910
raphespinal descendent fibers	27926
OECs	27957
one cell type	27971
olfactory mucosa , which is a tissue of considerable cellular complexity	27994
olfactory mucosa	27994
a tissue of considerable cellular complexity	28021
a tissue	28021
considerable cellular complexity	28033
This	28067
clinical trials involving the transplantation of these tissue samples in a complex injury such as the damaged central nervous system	28102
clinical trials	28102
the transplantation of these tissue samples	28128
the transplantation	28128
these tissue samples	28151
a complex injury such as the damaged central nervous system	28175
a complex injury	28175
the damaged central nervous system	28200
Lindsay et al. , 2010	28250
Lindsay	28250
et al.	28258
2010	28266
A better understanding of the effects of OLP and RLP transplantation in SCI animal models	28273
A better understanding	28273
the effects of OLP and RLP transplantation in SCI animal models	28299
the effects	28299
OLP and RLP transplantation in SCI animal models	28314
OLP and RLP transplantation	28314
SCI animal models	28345
the rationale	28399
the application of this treatment in humans	28417
the application	28417
this treatment in humans	28436
this treatment	28436
humans	28454
cells transplants combined with other therapies , such as the administration of MAG , OMP and NOGO-A inhibitors , growth-factors , and/or treadmill step training	28476
cells transplants	28476
other therapies , such as the administration of MAG , OMP and NOGO-A inhibitors , growth-factors	28508
other therapies	28508
the administration of MAG , OMP and NOGO-A inhibitors , growth-factors	28533
the administration	28533
MAG , OMP and NOGO-A inhibitors , growth-factors	28555
MAG , OMP and NOGO-A inhibitors	28555
growth-factors	28587
treadmill step training	28610
the possible beneficial results	28647
spinal cord injury	28685
Experimental procedure 4.1 .	28709
Experimental procedure	28709
4.1	28732
General Experimental procedures were approved by the Research Ethics Committee of the Universidade Federal	28737
General	28737
Experimental procedures	28745
the Research Ethics Committee of the Universidade Federal	28786
the Research Ethics Committee	28786
the Universidade Federal	28819
Rio Grande	28847
Sul -LRB- No. 2007892 -RRB-	28861
Sul	28861
No. 2007892	28866
The animals	28880
accordance with Arouca Brazilian law -LRB- 11794/2008 -RRB- and the National Institute of Health 's Guidelines	28910
accordance with Arouca Brazilian law -LRB- 11794/2008 -RRB-	28910
accordance	28910
Arouca Brazilian law -LRB- 11794/2008 -RRB-	28926
Arouca Brazilian law	28926
11794/2008	28948
the National Institute of Health 's Guidelines	28964
the National Institute	28964
Health 's Guidelines	28990
Health 's	28990
Care and Use of Laboratory Animals -LRB- publication No. 85-23 , revised 1985	29014
Care and Use	29014
Laboratory Animals -LRB- publication No. 85-23 , revised 1985	29030
Laboratory Animals -LRB- publication No. 85-23 ,	29030
Laboratory Animals	29030
publication No. 85-23	29050
publication No.	29050
85-23	29066
1985	29081
The animal handling recommendations of the Brazilian Society for Neurosciences and the International Brain Research Organization	29088
The animal	29088
recommendations of the Brazilian Society	29108
recommendations	29108
the Brazilian Society	29127
Neurosciences and the International Brain Research Organization	29153
Neurosciences	29153
the International Brain Research Organization	29171
A total of 108 male Wistar rats -LRB- local breeding colony -RRB- , 280 -- 380 g in body weight , and 13 weeks old	29237
A total	29237
108 male Wistar rats -LRB- local breeding colony -RRB- , 280 -- 380 g in body weight , and 13 weeks old	29248
108 male Wistar rats -LRB- local breeding colony -RRB- , 280	29248
108 male Wistar rats	29248
local breeding colony	29270
280	29294
380 g in body weight	29299
380 g	29299
body weight	29308
13 weeks	29325
this study	29351
Groups of two or three animals were maintained in standard plexigas boxes -LRB- 46 × 24 × 15 cm -RRB- , under 12:12 h light / dark cycle , in a temperature	29363
Groups of two or three animals were maintained in standard plexigas boxes -LRB- 46 × 24 × 15 cm -RRB- , under 12:12 h light	29363
Groups	29363
two or three animals were maintained in standard plexigas boxes -LRB- 46 × 24 × 15 cm -RRB-	29373
two	29373
three animals were maintained in standard plexigas boxes -LRB- 46 × 24 × 15 cm	29380
three animals	29380
standard plexigas	29413
boxes -LRB- 46 × 24 × 15 cm	29431
boxes -LRB- 46 × 24	29431
boxes	29431
46 × 24	29438
46	29438
24	29441
15 cm	29444
12:12 h light	29458
dark cycle , in a temperature	29473
dark cycle	29473
a temperature	29488
environment -LRB- 20 ± 2 °C -RRB- with food and water ad libitum	29513
environment -LRB- 20 ± 2 °C -RRB-	29513
environment	29513
20 ± 2 °C	29526
20 ±	29526
2 °C	29530
food and water ad libitum	29541
The animals	29568
the light phase of the photo cycle	29599
the light phase	29599
the photo cycle	29618
animals	29646
experimental animals -LRB- n = 72 -RRB- and lamina propria donors -LRB- n = 36 -RRB-	29672
experimental animals	29672
n	29694
72	29696
lamina propria donors	29704
n	29727
36	29729
Experimental animals -LRB- n = 72 -RRB-	29734
Experimental animals	29734
n	29756
72	29758
six groups : -LRB- 1 -RRB- AC -- rats submitted to RLP transplantation , immediately after spinal cord transection -LRB- n = 11 -RRB- ; -LRB- 2 -RRB- AT -- rats submitted to OLP transplantation , immediately after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 3 -RRB- 2WDC -- rats submitted to RLP transplantation , two weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 4 -RRB- 2WDT -- rats submitted to OLP transplantation , two weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 5 -RRB- 4WDC -- rats submitted to RLP transplantation , four weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 6 -RRB- 4WDT -- rats submitted to OLP transplantation , four weeks after spinal cord transection -LRB- n = 12 -RRB- .	29795
six groups : -LRB- 1 -RRB- AC -- rats submitted to RLP transplantation , immediately after spinal cord transection -LRB- n = 11 -RRB-	29795
six groups : -LRB- 1 -RRB- AC -- rats submitted to RLP transplantation , immediately after spinal cord transection	29795
six groups	29795
-LRB- 1 -RRB- AC -- rats submitted to RLP transplantation , immediately after spinal cord transection	29807
AC	29811
-- rats submitted to RLP transplantation , immediately	29813
-- rats submitted to RLP transplantation	29813
rats	29814
RLP transplantation	29832
immediately	29853
spinal	29871
n	29896
11	29898
-- rats submitted to OLP	29909
-- rats submitted to	29909
rats	29910
OLP	29928
transplantation , immediately after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 3 -RRB- 2WDC -- rats submitted to RLP transplantation , two weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 4 -RRB- 2WDT -- rats submitted to OLP transplantation , two weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 5 -RRB- 4WDC -- rats submitted to RLP transplantation , four weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 6 -RRB- 4WDT -- rats submitted to OLP transplantation , four weeks after spinal cord transection	29932
transplantation	29932
spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 3 -RRB- 2WDC -- rats submitted to RLP transplantation , two weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 4 -RRB- 2WDT -- rats submitted to OLP transplantation , two weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 5 -RRB- 4WDC -- rats submitted to RLP transplantation , four weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 6 -RRB- 4WDT -- rats submitted to OLP transplantation , four weeks after spinal cord transection	29967
spinal cord transection	29967
n	29992
12	29994
-LRB- 3 -RRB- 2WDC -- rats submitted to RLP transplantation , two weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 4 -RRB- 2WDT -- rats submitted to OLP transplantation , two weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 5 -RRB- 4WDC -- rats submitted to RLP transplantation , four weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 6 -RRB- 4WDT -- rats submitted to OLP transplantation , four weeks after spinal cord transection	29999
2WDC	30003
-- rats submitted to RLP transplantation , two weeks	30007
-- rats submitted to RLP transplantation	30007
rats	30008
RLP transplantation	30026
two weeks	30047
spinal cord	30063
transection -LRB- n = 12 -RRB- ; -LRB- 4 -RRB- 2WDT -- rats submitted to OLP transplantation , two weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 5 -RRB- 4WDC -- rats submitted to RLP transplantation , four weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 6 -RRB- 4WDT -- rats submitted to OLP transplantation , four weeks	30075
transection -LRB- n = 12 -RRB- ; -LRB- 4 -RRB- 2WDT -- rats submitted to OLP transplantation , two weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 5 -RRB- 4WDC -- rats submitted to RLP transplantation , four weeks after spinal cord transection -LRB- n = 12 -RRB-	30075
transection -LRB- n = 12 -RRB- ; -LRB- 4 -RRB- 2WDT -- rats submitted to OLP transplantation , two weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 5 -RRB- 4WDC -- rats submitted to RLP transplantation , four weeks after spinal cord transection	30075
transection -LRB- n = 12 -RRB-	30075
transection	30075
n	30088
12	30090
-LRB- 4 -RRB- 2WDT -- rats submitted to OLP transplantation , two weeks after spinal cord transection -LRB- n = 12 -RRB- ; -LRB- 5 -RRB- 4WDC -- rats submitted to RLP transplantation , four weeks after spinal cord transection	30095
2WDT	30099
-- rats submitted to OLP transplantation , two weeks	30103
-- rats submitted to OLP transplantation	30103
rats	30104
OLP transplantation	30122
two weeks	30143
spinal cord	30159
transection -LRB- n = 12 -RRB- ; -LRB- 5 -RRB- 4WDC -- rats submitted to RLP transplantation , four weeks	30171
transection	30171
n	30184
12	30186
-LRB- 5 -RRB- 4WDC -- rats submitted to RLP transplantation , four weeks	30191
-LRB- 5 -RRB- 4WDC	30191
rats submitted to RLP transplantation , four weeks	30200
rats	30200
RLP transplantation , four weeks	30218
RLP transplantation	30218
four weeks	30239
spinal cord transection	30256
n	30281
12	30283
-LRB- 6 -RRB- 4WDT -- rats submitted to OLP transplantation , four weeks	30288
-LRB- 6 -RRB- 4WDT	30288
-LRB- 6 -RRB-	30288
4WDT	30292
rats submitted to OLP transplantation , four weeks	30297
rats	30297
OLP transplantation , four weeks	30315
OLP transplantation	30315
four weeks	30336
spinal cord transection	30353
12	30380
All efforts	30385
the number of animals studied and their suffering	30419
the number	30419
animals studied and their suffering	30433
animals studied	30433
animals	30433
their suffering	30453
a previous studies	30489
a lesion-only group -LRB- i.e. , without any type of transplantation -RRB-	30509
a lesion-only group	30509
i.e. , without any type of transplantation	30530
i.e.	30530
any type of transplantation	30544
any type	30544
transplantation	30556
Lu et al. , 2001 , 2002 ; Steward et al. , 2006	30591
Lu	30591
et al. , 2001 , 2002 ; Steward et al. , 2006	30594
et al.	30594
2001	30602
2002 ; Steward et al.	30608
2002	30608
Steward et al.	30614
Steward	30614
et al.	30622
2006	30630
4.2	30638
Spinal cord transection	30643
spinal cord transection procedure	30671
animals	30706
anesthetized using pentobarbital -LRB- 40 mg/kg , i.p. , Cristália , São Paulo -- SP , Brazil -RRB- and maintained on a heating pad	30719
anesthetized	30719
40 mg/kg , i.p. , Cristália , São Paulo -- SP , Brazil	30753
40 mg/kg , i.p. , Cristália , São Paulo -- SP	30753
40 mg/kg , i.p. , Cristália , São Paulo --	30753
Cristália , São Paulo	30769
Cristália	30769
São Paulo	30780
Brazil	30795
a heating pad	30821
The hair overlying the area of interest	30836
The hair	30836
the area of interest	30855
the area	30855
interest	30867
the skin	30891
A midline incision	30913
the thoracic area was made	30935
the thoracic area	30935
muscle	30966
connective tissues	30974
the T8-T9 vertebrae	31018
a laminectomy	31045
the spinal cord	31060
two levels using microscissors -LRB- approximately 2 -- 3 mm apart -RRB-	31094
two levels	31094
microscissors -LRB- approximately 2 -- 3 mm apart -RRB-	31111
microscissors	31111
approximately 2 -- 3 mm apart	31126
approximately 2	31126
3 mm apart	31142
The segment between these incisions	31154
The segment	31154
these incisions	31174
a gap -LRB- Fig. 7A , left -RRB-	31211
a gap	31211
Fig. 7A , left	31218
Fig. 7A	31218
completeness of the lesion	31244
completeness	31244
the lesion	31260
the spinal cord stumps	31272
the vertebral canal	31325
a curved needle	31349
the lateral extension of vertebral canal	31384
the lateral extension	31384
vertebral canal	31409
lesion center -LRB- Ilha et al. , 2011 ; Ramón-Cueto et al. , 2000 -RRB-	31428
lesion center	31428
Ilha	31443
et al. , 2011 ; Ramón-Cueto et al. , 2000	31448
et al.	31448
2011 ; Ramón-Cueto et al.	31456
2011	31456
Ramón-Cueto et al.	31462
Ramón-Cueto	31462
et al.	31474
2000	31482
A piece of hemostatic sponge -LRB- Technew , São Paulo -- SP , Brazil -RRB-	31489
A piece	31489
hemostatic sponge -LRB- Technew , São Paulo -- SP , Brazil -RRB-	31500
hemostatic sponge	31500
Technew , São Paulo -- SP , Brazil	31519
Technew , São Paulo	31519
SP , Brazil	31538
SP	31538
Brazil	31542
the transection site	31564
muscles , connective tissue and skin	31595
muscles	31595
connective tissue	31604
skin	31626
The animals	31645
recovery	31682
4.3	31693
Post-operative care Animals	31698
the analgesic Dimorph -LRB- morphine sulfate , s.c. , 0.08 -- 0.16 mg/kg , Cristália , São Paulo -- SP , Brazil -RRB-	31735
the analgesic Dimorph	31735
morphine sulfate , s.c. , 0.08 -- 0.16 mg/kg , Cristália , São Paulo -- SP , Brazil	31758
morphine sulfate	31758
s.c. , 0.08 -- 0.16 mg/kg , Cristália , São Paulo -- SP	31776
s.c.	31776
0.08 -- 0.16 mg/kg , Cristália , São Paulo -- SP	31782
0.08	31782
0.16 mg/kg , Cristália , São Paulo	31787
0.16 mg/kg	31787
Cristália	31799
São Paulo	31810
SP	31820
Brazil	31824
twice a day	31832
the first 4 days post-injury	31852
the first 4 days	31852
Rats	31882
Baytril -LRB- Enrofloxacin , s.c. , 2.5 mg/kg , Bayer , São Paulo -- SP , Brazil -RRB-	31927
Baytril	31927
Enrofloxacin , s.c. , 2.5 mg/kg , Bayer	31936
Enrofloxacin	31936
s.c.	31950
2.5 mg/kg	31956
Bayer	31967
São Paulo -- SP , Brazil	31974
São Paulo	31974
SP , Brazil	31984
SP	31984
Brazil	31988
urinary tract infections	32007
14 days	32036
Bladders	32045
twice a day	32078
it	32096
the animal	32153
an automatic bladder voidance reflex -LRB- 15 -- 20 days -RRB-	32178
an automatic bladder voidance reflex	32178
15 -- 20 days	32216
15	32216
20 days	32219
Animals	32229
infections and general health	32262
infections	32262
general health	32277
the post-injury survival period	32303
Animals	32336
autophagia	32360
the experimental period	32378
4.4	32404
Dissection and lamina propria preparation OLP and RLP were dissected according to the method	32409
Dissection and lamina propria preparation	32409
OLP and RLP	32451
the method	32491
Steward	32515
et al. -LRB- 2006 -RRB-	32523
et al.	32523
2006	32531
Donors male Wistar rats -LRB- n = 36 -RRB- , 280 -- 380 g in body weight and 13 weeks old ,	32538
Donors male Wistar rats -LRB- n = 36 -RRB-	32538
Donors	32538
male Wistar rats -LRB- n = 36 -RRB-	32545
male Wistar rats	32545
n	32563
36	32565
280 -- 380 g in body weight and 13 weeks old	32570
280	32570
380 g in body weight and 13 weeks	32574
380 g	32574
body weight and 13 weeks	32583
body weight	32583
13 weeks	32599
The head	32631
the midline in such a way	32662
the midline	32662
such a way	32677
visualization of the nasal septum and OB	32700
visualization	32700
the nasal septum and OB	32717
The nasal septum	32742
microscissors	32777
a Petri dish	32805
Dulbecco 's	32829
Eagle Medium/Ham 's Nutrient Mixture F12 tissue culture media -LRB- DMEN/F12 , Sigma-Aldrich , USA -RRB-	32849
Eagle Medium/Ham 's Nutrient Mixture F12 tissue culture media	32849
Eagle Medium/Ham 's Nutrient Mixture F12 tissue	32849
Eagle Medium/Ham 's	32849
culture media	32896
DMEN/F12	32911
Sigma-Aldrich	32921
USA	32936
Olfactory mucosa bilaterally lines the posterior part of the nasal septum and its lamina propria	32942
Olfactory mucosa	32942
lines the posterior part of the nasal septum and its lamina propria	32971
lines	32971
the posterior part of the nasal septum and its lamina propria	32977
the posterior part	32977
the nasal septum and its lamina propria	32999
the nasal septum	32999
its lamina propria	33020
OECs	33048
Fig. 8A	33054
a coronal section of the olfactory mucosa	33068
a coronal section	33068
the olfactory mucosa	33089
the olfactory epithelium and OECs in lamina propria	33116
the olfactory epithelium	33116
OECs in lamina propria	33145
OECs	33145
lamina propria	33153
These fusiform glial cells	33169
their immunoreactivity for p75 neurotrophin receptor -LRB- rabbit anti-p75NTR , 1:300 , Sigma - Aldrich , USA , N3908 -RRB- , S-100 -LRB- rabbit anti-S-100 , 1:600 , Sigma - Aldrich , USA , S2644 -RRB- and GFAP in low intensity -LRB- mouse anti-GFAP , 1:400 , Sigma-Aldrich , USA , G3893 -RRB- -LRB- Ramer et al. , 2004 ; Ramón-Cueto and Avila , 1998 -RRB-	33215
their immunoreactivity	33215
p75 neurotrophin receptor -LRB- rabbit anti-p75NTR , 1:300 , Sigma - Aldrich , USA , N3908 -RRB- , S-100 -LRB- rabbit anti-S-100 , 1:600 , Sigma - Aldrich , USA , S2644 -RRB- and GFAP in low intensity -LRB- mouse anti-GFAP , 1:400 , Sigma-Aldrich , USA , G3893 -RRB- -LRB- Ramer et al. , 2004 ; Ramón-Cueto and Avila , 1998 -RRB-	33242
p75 neurotrophin receptor -LRB- rabbit anti-p75NTR , 1:300 , Sigma - Aldrich , USA , N3908 -RRB-	33242
p75 neurotrophin receptor	33242
rabbit anti-p75NTR , 1:300	33269
rabbit anti-p75NTR	33269
1:300	33289
Sigma - Aldrich , USA , N3908	33296
Sigma	33296
Aldrich , USA , N3908	33303
Aldrich , USA	33303
N3908	33317
S-100 -LRB- rabbit anti-S-100 , 1:600 , Sigma - Aldrich , USA , S2644 -RRB-	33325
S-100	33325
rabbit anti-S-100 , 1:600	33332
rabbit anti-S-100	33332
1:600	33351
Sigma - Aldrich , USA , S2644	33358
Sigma	33358
Aldrich , USA , S2644	33365
Aldrich , USA	33365
S2644	33379
GFAP in low intensity -LRB- mouse anti-GFAP , 1:400 , Sigma-Aldrich , USA , G3893 -RRB- -LRB- Ramer et al. , 2004 ; Ramón-Cueto and Avila , 1998 -RRB-	33390
GFAP	33390
low intensity -LRB- mouse anti-GFAP , 1:400 , Sigma-Aldrich , USA , G3893 -RRB- -LRB- Ramer et al. , 2004 ; Ramón-Cueto and Avila , 1998 -RRB-	33398
low intensity -LRB- mouse anti-GFAP , 1:400 , Sigma-Aldrich , USA , G3893 -RRB-	33398
low intensity	33398
mouse anti-GFAP , 1:400 , Sigma-Aldrich , USA , G3893	33413
mouse anti-GFAP	33413
1:400	33430
Sigma-Aldrich	33437
USA	33452
G3893	33457
Ramer	33465
et al. , 2004 ; Ramón-Cueto and Avila , 1998	33471
et al.	33471
2004 ; Ramón-Cueto and Avila	33479
2004	33479
Ramón-Cueto and Avila	33485
1998	33508
Respiratory mucosa	33515
olfactory mucosa	33550
the dorso-anterior part of the nasal septum	33590
the dorso-anterior part	33590
the nasal septum	33617
Fig. 8B	33647
RLP	33656
OECs	33673
p75 , S - 100 and GFAP markers alone are not exclusive to these glial cells and the staining observed in RLP	33688
p75 , S - 100 and GFAP markers	33688
p75	33688
S	33693
100	33696
GFAP markers	33704
these glial cells and the staining observed in RLP	33744
these glial cells	33744
the staining observed in RLP	33766
the staining	33766
RLP	33791
the presence of Schwann cells	33815
the presence	33815
Schwann cells	33831
the trigeminal nerve -LRB- Mackay-Sim and St John , 2011 -RRB-	33850
the trigeminal nerve	33850
Mackay-Sim and St John , 2011	33872
Mackay-Sim and St John ,	33872
2011	33896
a scalpel	33909
two similar sized pieces of olfactory or respiratory mucosa	33920
two similar sized pieces	33920
two	33920
olfactory or respiratory mucosa	33948
the donor 's nasal septum	34000
the donor 's	34000
ice-cold DMEN/F12	34051
the respiratory tissue dissection	34073
the vomeronasal nerve	34108
Olfactory and respiratory tissues were separately	34143
Olfactory and respiratory tissues	34143
2.4 units/mL dispase II solution -LRB- Sigma-Aldrich , Germany , D4693 -RRB-	34208
2.4 units/mL dispase II solution	34208
Sigma-Aldrich	34242
Germany	34257
D4693	34266
37 °C	34276
enzymatic digestion	34289
both types of lamina propria samples	34310
both types	34310
lamina propria samples	34324
the epithelium using a micro-spatula under a dissection microscope	34377
the epithelium	34377
a micro-spatula	34398
a dissection microscope	34420
small pieces	34462
approximately 3 -- 4mm2	34476
approximately 3	34476
4mm2	34493
grafting	34502
the tissue	34519
Hank 's Buffered Salt Solution -LRB- HBSS , Sigma-Aldrich , Brazil -RRB-	34546
Hank 's Buffered Salt Solution	34546
Hank 's	34546
HBSS	34577
Sigma-Aldrich	34583
Brazil	34598
iced DMEM/F12	34620
transplantation	34640
the host	34661
4.5	34672
Transplantation of OLP and RLP	34677
Transplantation	34677
OLP and RLP	34696
The acute animal groups were transplanted immediately after spinal cord transection with RLP -LRB- AC group -RRB- or OLP	34708
The acute animal	34708
groups	34725
spinal cord transection	34768
RLP -LRB- AC group -RRB- or OLP	34797
RLP -LRB- AC group -RRB-	34797
RLP	34797
AC group	34802
OLP	34815
group	34823
The other animal groups	34831
RLP and OLP grafts 2 weeks post-SCI -LRB- 2WDC and 2WDT groups , respectively -RRB- and 4 weeks post-SCI -LRB- 4WDC and 4WDT groups , respectively -RRB-	34864
RLP and OLP grafts	34864
2 weeks	34883
2WDC and 2WDT groups , respectively	34901
2WDC and 2WDT groups	34901
4 weeks	34941
4WDC and 4WDT groups , respectively	34959
4WDC and 4WDT groups	34959
this procedure	35000
rats	35016
the original incision	35067
Scar tissue	35104
the gap between the rostral and caudal stumps	35132
the gap	35132
the rostral and caudal stumps	35148
the rostral	35148
caudal stumps	35164
pieces of respiratory -LRB- 2WDC and 4WDC groups -RRB- or olfactory -LRB- 2WDT and 4WDT groups -RRB- lamina propria -LRB- Fig. 7A , right -RRB-	35194
pieces	35194
respiratory -LRB- 2WDC and 4WDC groups -RRB- or olfactory -LRB- 2WDT and 4WDT groups -RRB- lamina propria -LRB- Fig. 7A , right -RRB-	35204
respiratory -LRB- 2WDC and 4WDC groups -RRB- or olfactory -LRB- 2WDT and 4WDT groups -RRB- lamina propria	35204
2WDC and 4WDC groups	35217
2WDC	35217
4WDC groups	35226
2WDT and 4WDT groups	35253
2WDT	35253
4WDT groups	35262
Fig. 7A , right	35291
Fig. 7A	35291
right	35300
A piece of hemostatic sponge -LRB- Hemospon , Technew , São Paulo -- SP , Brazil -RRB-	35308
A piece of hemostatic sponge	35308
A piece	35308
hemostatic sponge	35319
Hemospon , Technew , São Paulo -- SP , Brazil	35338
Hemospon , Technew , São Paulo	35338
SP , Brazil	35368
SP	35368
Brazil	35372
the transplantation site	35396
blood homeostasis	35431
muscle and skin layers	35457
post-operatory care	35497
Approximately 18 weeks after spinal cord injury , the viability of grafted tissue	35557
Approximately 18 weeks	35557
spinal cord injury , the viability of grafted tissue	35586
spinal cord injury	35586
the viability of grafted tissue	35606
the viability	35606
grafted tissue	35623
the presence of fusiform-shaped OECs immunoreactive for p75NTR , S-100 and GFAP	35658
the presence	35658
fusiform-shaped OECs immunoreactive for p75NTR , S-100 and GFAP	35674
fusiform-shaped OECs	35674
p75NTR , S-100 and GFAP	35714
the site of spinal cord transection -LRB- Fig. 8C -RRB-	35740
the site	35740
spinal cord transection -LRB- Fig. 8C -RRB-	35752
spinal cord transection	35752
Fig. 8C	35777
RLP control grafts	35787
OECs	35832
the lack of cells expressing the three markers used in the lesion area -LRB- Fig. 8D -RRB-	35854
the lack	35854
cells expressing the three markers used in the lesion area -LRB- Fig. 8D -RRB-	35866
cells	35866
the three markers used in the lesion area -LRB- Fig. 8D -RRB-	35883
the three markers	35883
the lesion area -LRB- Fig. 8D -RRB-	35909
the lesion area	35909
Fig. 8D	35926
4.6	35937
Behavioral assessment Hindlimbmotor function	35942
the BBB locomotor rating -LRB- Basso et al. , 1996 -RRB-	36006
the BBB locomotor rating	36006
Basso	36032
et al. , 1996	36038
et al.	36038
1996	36046
This scale	36053
the functional recovery of hindlimbs	36117
the functional recovery	36117
hindlimbs	36144
lesions in thoracic spinal cord	36160
lesions	36160
thoracic spinal cord	36171
The score of this scale	36193
The score	36193
this scale	36206
0 -LRB- no hindlimb movement -RRB-	36229
0	36229
no hindlimb movement	36232
21 -LRB- normal movement of the hindlimbs -RRB-	36257
21	36257
normal movement of the hindlimbs	36261
normal movement	36261
the hindlimbs	36280
this study	36299
BBB assessment	36311
the SCI -LRB- at days 5 , 20 , 35 , 50 , 65 , 80 post-injury for the AC and AT groups ; at days 5 , 20 , 35 , 50 , 65 , 80 , 95 post-injury for the 2WDC and 2WDT groups ; and at days 5 , 20 , 35 , 50 , 65 , 80 , 95 , 110 post-injury for the 4WDC and 4WDT groups -RRB-	36392
the SCI	36392
days	36404
5 , 20 , 35 , 50 , 65 , 80 post-injury for the AC and AT groups	36409
5	36409
20	36412
35	36416
50	36420
65	36424
80 post-injury for the AC and AT groups	36428
80	36428
the AC	36447
groups	36461
days	36472
5 , 20 , 35 , 50 , 65 , 80 , 95 post-injury for the 2WDC and 2WDT groups ; and at days 5 , 20 , 35 , 50 , 65 , 80 , 95 , 110 post-injury for the 4WDC and 4WDT groups	36477
5	36477
20	36480
35	36484
50	36488
65	36492
80 , 95 post-injury for the 2WDC and 2WDT groups ; and at days 5 , 20 , 35 , 50 , 65 , 80 , 95 , 110 post-injury for the 4WDC and 4WDT groups	36496
80 , 95 post-injury for the 2WDC and 2WDT groups ; and at days 5 , 20 , 35 , 50 , 65 , 80 , 95 , 110 post-injury	36496
80	36496
95	36500
the 2WDC and 2WDT groups	36519
days 5 , 20 , 35 , 50 , 65 , 80 , 95	36552
days 5	36552
20	36560
35	36564
50	36568
65	36572
80	36576
95	36580
110	36584
the 4WDC and 4WDT groups	36604
each test	36635
rats	36646
an open-field -LRB- 60 × 30 × 40 cm -RRB- for 5 min	36666
an open-field -LRB- 60 × 30 × 40 cm -RRB-	36666
an open-field	36666
60 × 30 × 40 cm	36681
60	36681
× 30 × 40 cm	36683
× 30	36683
40 cm	36687
5 min	36698
The test session	36704
a video camera -LRB- Sony Handycam DCR-SR88 , São Paulo -- SP , Brazil -RRB-	36739
a video camera	36739
Sony Handycam DCR-SR88 , São Paulo -- SP , Brazil	36755
Sony Handycam DCR-SR88	36755
São Paulo -- SP	36779
São Paulo	36779
SP	36789
Brazil	36793
later analysis	36810
a blinded observer	36828
The scores of the left and right hindlimbs	36848
The scores	36848
the left and right hindlimbs	36862
the BBB score of each animal	36918
the BBB score	36918
each animal	36935
4.7	36949
Retrograde tracer injection	36954
the end of behavioral analysis	36985
the end	36985
behavioral analysis	36996
rats	37017
An incision	37060
the T12 vertebrae level	37084
the spinal cord	37118
the SCI site	37140
a laminectomy	37160
FG retrograde tracer -LRB- 2 % dextran tetramethylenerhodamine , Biotium Inc. , Hayward -- CA , USA -RRB-	37175
FG retrograde tracer	37175
2 % dextran tetramethylenerhodamine , Biotium Inc.	37197
2 % dextran tetramethylenerhodamine	37197
Biotium Inc.	37233
Hayward -- CA , USA	37247
Hayward	37247
CA , USA	37255
a stereotaxic apparatus -LRB- Insight , Ribeirão Preto -- SP , Brazil -RRB- coupled to a 1 μL Hamilton syringe -LRB- Hamilton Company , Reno -- NV , USA -RRB-	37283
a stereotaxic apparatus	37283
Insight , Ribeirão Preto -- SP , Brazil	37308
Insight , Ribeirão Preto	37308
SP , Brazil	37332
SP	37332
Brazil	37336
a 1 μL Hamilton syringe -LRB- Hamilton Company , Reno -- NV , USA -RRB-	37355
a 1 μL Hamilton syringe	37355
1 μL	37357
Hamilton Company , Reno -- NV , USA	37380
Hamilton Company , Reno	37380
NV , USA	37403
Three injections of FG -LRB- 0.05 μL , 1 min duration each -RRB-	37413
Three injections of FG	37413
Three injections	37413
FG	37433
0.05 μL , 1 min duration each	37437
0.05 μL	37437
1 min duration each	37446
1 min duration	37446
each	37460
midline -LRB- 0.5 , 0.8 and 1.5 mm deep -RRB- and 1 mm laterally -LRB- 0.5 , 0.8 and 1.2 mm deep -RRB-	37479
midline -LRB- 0.5 , 0.8 and 1.5 mm deep -RRB-	37479
midline	37479
0.5 , 0.8 and 1.5 mm	37488
0.5	37488
0.8	37493
1.5 mm	37501
1 mm laterally -LRB- 0.5 , 0.8 and 1.2 mm deep -RRB-	37517
1 mm laterally	37517
1 mm	37517
0.5 , 0.8 and 1.2 mm	37533
0.5	37533
0.8	37538
1.2 mm	37546
each side of this spinal cord level -LRB- Steward et al. , 2006 -RRB-	37561
each side	37561
this spinal cord level -LRB- Steward et al. , 2006 -RRB-	37574
this spinal cord level	37574
Steward	37598
et al. , 2006	37606
et al.	37606
2006	37614
Post-operatory care	37621
4.8	37676
Tissue preparation and immunohistochemistry One week after the retrograde	37681
Tissue preparation and immunohistochemistry	37681
One week	37725
the retrograde	37740
injections	37763
rats	37775
an overdose of pentobarbital -LRB- 100mg/kg body weight , i.p. , Cristália , São Paulo -- SP , Brazil -RRB-	37789
an overdose	37789
pentobarbital -LRB- 100mg/kg body weight , i.p. , Cristália , São Paulo -- SP , Brazil -RRB-	37804
pentobarbital	37804
100mg/kg body weight , i.p. , Cristália , São Paulo -- SP , Brazil	37819
100mg/kg body weight , i.p. , Cristália , São Paulo -- SP	37819
100mg/kg body weight , i.p. , Cristália , São Paulo --	37819
100mg/kg body weight	37819
Cristália , São Paulo	37847
Cristália	37847
São Paulo	37858
Brazil	37872
saline solution	37918
4 % paraformaldehyde -LRB- pH 7.4 -RRB- using a peristaltic pump -LRB- 30mL/min , Milan Equipamentos Científicos , Colombo -- PR , Brazil -RRB-	37947
4 % paraformaldehyde -LRB- pH 7.4 -RRB-	37947
4 % paraformaldehyde	37947
pH 7.4	37968
a peristaltic pump	37982
30mL/min , Milan Equipamentos Científicos	38002
30mL/min	38002
Milan Equipamentos Científicos	38012
Colombo -- PR , Brazil	38044
Colombo	38044
PR , Brazil	38052
PR	38052
Brazil	38056
Brain , brainstemand thoracic spinal cord with approximately 2-cmlong -LRB- including the lesion site -RRB-	38065
Brain	38065
brainstemand thoracic spinal cord with approximately 2-cmlong -LRB- including the lesion site -RRB-	38072
brainstemand thoracic spinal cord	38072
approximately 2-cmlong -LRB- including the lesion site -RRB-	38111
approximately 2-cmlong	38111
the lesion site	38145
the same fixative solution	38189
15 % and 30 % sucrose in phosphate buffer saline -LRB- PBS -RRB-	38237
15 % and 30 % sucrose	38237
phosphate buffer saline -LRB- PBS -RRB-	38260
phosphate buffer saline	38260
PBS	38285
embedding in Tissue-Tek	38300
embedding	38300
Tissue-Tek	38313
spinal cord samples	38325
a digital camera -LRB- Sony Cyber-Shot DSC-S950 , São Paulo -- SP , Brazil -RRB- on a dark background	38368
a digital camera -LRB- Sony Cyber-Shot DSC-S950 , São Paulo -- SP , Brazil -RRB-	38368
a digital camera	38368
Sony Cyber-Shot DSC-S950 , São Paulo -- SP , Brazil	38386
Sony Cyber-Shot DSC-S950	38386
São Paulo -- SP	38412
São Paulo	38412
SP	38422
Brazil	38426
a dark background	38437
morphological visualization of the injury site -LRB- Fig. 7B -RRB-	38466
morphological visualization	38466
the injury site -LRB- Fig. 7B -RRB-	38497
the injury site	38497
Fig. 7B	38514
this	38530
samples	38536
isopentane -LRB- Merck , Germany -RRB- cooled in liquid nitrogen	38567
isopentane	38567
Merck	38579
Germany	38586
liquid nitrogen	38605
− 80 °C	38635
Primary somatosensory cortex , primary and secondary motor cortex and the entire brainstem	38643
Primary somatosensory cortex , primary and secondary motor cortex	38643
the entire brainstem	38712
200 μm thick , 150 μm apart	38755
200 μm thick	38755
200 μm	38755
150 μm	38769
a cryostat -LRB- CM1850 , Leica , São Paulo -- SP , Brazil -RRB-	38789
a cryostat	38789
CM1850 , Leica	38801
CM1850	38801
Leica	38809
São Paulo -- SP , Brazil	38816
São Paulo	38816
SP , Brazil	38826
SP	38826
Brazil	38830
retrograde tracer visualization	38847
These sections	38880
gelatin-coated glass slides , covered with aqueous mounting medium -LRB- FluorSave , Calbiochem , Darmstadt , Germany -RRB- and coverslips	38911
gelatin-coated glass slides	38911
aqueous mounting medium -LRB- FluorSave , Calbiochem , Darmstadt , Germany -RRB- and coverslips	38953
aqueous mounting medium -LRB- FluorSave , Calbiochem , Darmstadt , Germany -RRB-	38953
aqueous mounting medium	38953
FluorSave	38978
Calbiochem	38989
Darmstadt , Germany	39001
coverslips	39025
The entire spinal cord samples were longitudinally cut -LRB- 25 μm -RRB- , in a series of 5 slides per animal with 7 -- 8 sections per slide .	39037
The entire spinal cord samples were longitudinally cut -LRB- 25 μm -RRB- , in a series of 5 slides per animal with 7	39037
The entire spinal cord samples were longitudinally cut -LRB- 25 μm -RRB-	39037
The entire spinal cord	39037
samples	39060
25 μm	39093
a series of 5 slides per animal with 7	39104
a series	39104
5 slides per animal with 7	39116
5 slides	39116
animal with 7	39129
animal	39129
7	39141
8 sections per slide	39143
8 sections	39143
slide	39158
Two slides per animal	39165
Two slides	39165
animal	39180
immunohistochemistry	39208
the peroxidase method -LRB- Sternberger , 1979 -RRB-	39232
the peroxidase method	39232
Sternberger	39255
1979	39268
sections	39286
PBS	39310
a 30 min period with 3 % hydrogen peroxide -LRB- H2O2 -RRB-	39327
a 30 min period	39327
3 % hydrogen peroxide -LRB- H2O2 -RRB-	39348
3 % hydrogen peroxide	39348
H2O2	39370
several washes in PBS	39383
several washes	39383
PBS	39401
sections	39406
1 % albumin solution	39437
0.4 % triton X-100 -LRB- PBS-Tx -RRB-	39462
0.4 % triton X-100	39462
PBS-Tx	39481
slices	39496
48 h	39522
4 °C in either GFAP -LRB- rabbit anti-GFAP , 1:200 , DAKO Denmark A/S , Denmark , Z0334 -RRB- or GAP-43 antibodies -LRB- mouse anti-GAP - 43 , 1:500 , Santa Cruz Biotechnology Inc. , USA , SC33705 -RRB-	39530
4 °C	39530
either GFAP -LRB- rabbit anti-GFAP , 1:200 , DAKO Denmark A/S , Denmark , Z0334 -RRB- or GAP-43 antibodies -LRB- mouse anti-GAP - 43 , 1:500 , Santa Cruz Biotechnology Inc. , USA , SC33705 -RRB-	39538
either GFAP	39538
rabbit anti-GFAP , 1:200 , DAKO Denmark A/S , Denmark , Z0334	39551
rabbit anti-GFAP	39551
1:200	39569
DAKO Denmark A/S	39576
Denmark	39594
Z0334	39603
GAP-43 antibodies	39613
mouse anti-GAP	39632
43 , 1:500 , Santa Cruz Biotechnology Inc. , USA , SC33705	39648
43	39648
1:500	39652
Santa Cruz Biotechnology Inc.	39659
USA	39690
SC33705	39695
Sections	39705
PBS-Tx and re-incubated	39729
goat antirabbit IgG -LRB- 1:100 , Sigma-Aldrich , USA , R2004 -RRB- or goat antimouse IgG -LRB- 1:100 , Sigma-Aldrich , USA , M8642 -RRB-	39756
goat antirabbit IgG	39756
1:100	39777
Sigma-Aldrich , USA	39784
R2004	39804
goat antimouse IgG	39814
1:100	39834
Sigma-Aldrich , USA	39841
M8642	39861
2 h. Following PBS	39872
2 h.	39872
PBS	39887
slices	39899
peroxidase antiperoxidase -LRB- 1:500 , Sigma-Aldrich , USA , P1291 -RRB- for 1 h and 30 min	39921
peroxidase antiperoxidase -LRB- 1:500 , Sigma-Aldrich , USA , P1291 -RRB-	39921
peroxidase antiperoxidase	39921
1:500	39948
Sigma-Aldrich , USA	39955
P1291	39975
1 h and 30 min	39986
1 h	39986
30 min	39994
The immunohistochemical reaction	40002
the slices	40063
a medium containing 0.06 % 3,3 diaminobenzidine -LRB- DAB , Sigma-Aldrich , USA , D5637 -RRB-	40077
a medium	40077
0.06 % 3,3 diaminobenzidine -LRB- DAB , Sigma-Aldrich , USA , D5637 -RRB-	40097
0.06 % 3,3 diaminobenzidine	40097
0.06 %	40097
3,3 diaminobenzidine	40103
DAB	40125
Sigma-Aldrich , USA	40130
D5637	40150
the same solution	40169
1 μM of 3 % H2O2 per mL of DAB medium	40198
1 μM	40198
3 % H2O2 per mL of DAB medium	40206
3 % H2O2	40206
mL of DAB medium	40218
mL	40218
DAB medium	40224
10 min each	40239
10 min	40239
each	40246
slices	40261
PBS	40285
ethanol	40306
xylene	40328
Permount and coverslips	40352
Control sections	40377
the primary antibody	40420
it	40455
PBS	40463
double staining protocols	40471
fibre tracts	40498
the following antibodies : rabbit anti-serotonin -LRB- 1:5000 , Sigma - Aldrich , USA , S5545 -RRB- for serotonergic axons	40530
the following antibodies	40530
rabbit anti-serotonin -LRB- 1:5000 , Sigma - Aldrich , USA , S5545 -RRB- for serotonergic axons	40556
rabbit anti-serotonin -LRB- 1:5000 , Sigma - Aldrich , USA , S5545 -RRB-	40556
rabbit anti-serotonin	40556
1:5000 , Sigma	40579
1:5000	40579
Sigma	40587
Aldrich , USA , S5545	40594
Aldrich	40594
USA	40603
S5545	40608
serotonergic axons	40619
the spinal cord coming from raphe nuclei ; and rabbit anti-CGRP -LRB- 1:1500 , courtesy of Dr. Rodrigo , Instituto Cajal , Spain -RRB- as a marker for ascending sensory neurons	40641
the spinal cord	40641
raphe nuclei ; and rabbit anti-CGRP -LRB- 1:1500 , courtesy of Dr. Rodrigo , Instituto Cajal , Spain -RRB-	40669
raphe nuclei	40669
rabbit anti-CGRP	40687
1:1500 , courtesy of Dr. Rodrigo , Instituto Cajal , Spain	40705
1:1500	40705
courtesy of Dr. Rodrigo , Instituto Cajal	40713
courtesy	40713
Dr. Rodrigo , Instituto Cajal	40725
Dr. Rodrigo	40725
Instituto Cajal	40738
Spain	40755
a marker for ascending sensory neurons	40765
a marker	40765
sensory neurons	40788
Fibrous scar borders	40805
immunoreactivity	40845
GFAP -LRB- mouse anti-GFAP , 1:400 , Sigma-Aldrich , USA , G3893 -RRB-	40865
GFAP	40865
mouse anti-GFAP , 1:400 , Sigma-Aldrich , USA , G3893	40871
mouse anti-GFAP	40871
1:400	40888
Sigma-Aldrich	40895
USA	40910
G3893	40915
The protocol	40923
the sections	40957
PBS	40975
permeabilization with 0.25 % PBS-Tx	40992
permeabilization	40992
0.25 % PBS-Tx	41014
this	41034
sections	41040
1 % albumin for 30 min	41065
1 % albumin	41065
30 min	41080
Incubation with the first antibodies	41088
Incubation	41088
the first antibodies	41104
1 % albumin in PBS-Tx	41144
1 % albumin	41144
PBS-Tx	41158
4 °C for 48 h. Following PBS washes	41168
4 °C	41168
48 h. Following PBS washes	41177
48 h.	41177
PBS washes	41193
PBS	41193
sections	41205
secondary antibodies anti-mouse Alexa 488 -LRB- 1:500 , Molecular Probes , Invitrogen , USA , A10680 -RRB- and anti-rabbit Alexa 555 -LRB- 1:500 , Molecular Probes , Invitrogen , USA , A21428 -RRB-	41232
secondary antibodies anti-mouse Alexa 488 -LRB- 1:500 , Molecular Probes , Invitrogen , USA , A10680 -RRB-	41232
secondary antibodies anti-mouse Alexa 488	41232
secondary antibodies	41232
Alexa 488	41264
1:500 , Molecular Probes , Invitrogen , USA , A10680	41275
1:500	41275
Molecular Probes	41282
Invitrogen	41300
USA	41312
A10680	41317
anti-rabbit Alexa 555 -LRB- 1:500 , Molecular Probes , Invitrogen , USA , A21428 -RRB-	41329
anti-rabbit Alexa 555	41329
1:500 , Molecular Probes , Invitrogen , USA , A21428	41352
1:500	41352
Molecular Probes	41359
Invitrogen	41377
USA	41389
A21428	41394
The slides	41403
aqueous mounting medium -LRB- FluorSave , Calbiochem , Darmstadt , Germany -RRB- and coverslips	41432
aqueous mounting medium -LRB- FluorSave , Calbiochem , Darmstadt , Germany -RRB-	41432
aqueous mounting medium	41432
FluorSave	41457
Calbiochem	41468
Darmstadt , Germany	41480
coverslips	41504
4.9	41517
Image analysis 4.9.1 .	41522
Image analysis	41522
4.9.1	41537
Retrograde tracing assessment Sections from the entire brainstem and sensorimotor cortex -LRB- n = 3 per group -RRB-	41544
Retrograde	41544
assessment Sections	41563
the entire brainstem and sensorimotor cortex -LRB- n = 3 per group -RRB-	41588
the entire brainstem and sensorimotor cortex	41588
n = 3 per group	41634
n = 3	41634
n	41634
3	41636
group	41642
serial stack images -LRB- 11.96 μm thick , 16 -- 17 serial stack images per slice -RRB- obtained with an Olympus confocal FV-1000	41668
serial	41668
images -LRB- 11.96 μm thick , 16 -- 17 serial stack images per slice -RRB- obtained with an Olympus confocal FV-1000	41681
images	41681
11.96 μm thick , 16	41689
11.96 μm thick	41689
11.96 μm	41689
16	41705
17 serial	41708
images per slice	41724
images	41724
slice	41735
an Olympus confocal FV-1000	41756
Plan-Apochromat 10 × objective lens	41785
Plan-Apochromat 10	41785
× objective lens	41803
Numerical aperture - NA 0.30	41831
Numerical aperture	41831
NA 0.30	41852
the pinhole	41865
automatic mode	41888
The FG signal -LRB- blue -RRB-	41904
The FG signal	41904
blue	41919
a wide band ultraviolet excitation filter -LRB- Excitation -- 331 nm , Emission -- 418 nm -RRB-	41945
a wide band ultraviolet excitation filter	41945
Excitation -- 331 nm	41988
Excitation	41988
331 nm	41999
Emission -- 418 nm	42007
Emission	42007
418 nm	42016
Images	42025
a photomultiplier detector and all pictures	42048
a photomultiplier detector	42048
all pictures	42079
Image J	42111
Software 1.42 q -LRB- Wayne Rasband , National Institutes of Health , USA -RRB-	42119
Software 1.42 q	42119
Wayne Rasband , National Institutes of Health , USA	42135
Wayne Rasband	42135
National Institutes of Health	42150
National Institutes	42150
Health	42173
USA	42181
The total number of FG labeled neurons in the propriospinal and selected supraspinal regions , i.e. , MdV/MdD -LRB- 5 slices per animal on average -RRB- , PnO / PnC -LRB- 7 slices per animal on average -RRB- , Ra -LRB- including the raphe pallidus , raphe obscurus , raphe magnus -- 20 slices per animal on average -RRB- , SpVe -LRB- 7 slices per animal on average -RRB- , LVe -LRB- 6 slices per animal on average -RRB- , locus coeruleus -LRB- LC -- 4 slices per animal on average -RRB- , M1/M2 -LRB- 25 slices per animal on average -RRB- and S1 -LRB- 20 slices per animal on average -RRB-	42187
The total number	42187
FG labeled neurons in the propriospinal and selected supraspinal regions , i.e. , MdV/MdD -LRB- 5 slices per animal on average -RRB- , PnO / PnC -LRB- 7 slices per animal on average -RRB- , Ra -LRB- including the raphe pallidus , raphe obscurus , raphe magnus -- 20 slices per animal on average -RRB- , SpVe -LRB- 7 slices per animal on average -RRB- , LVe -LRB- 6 slices per animal on average -RRB- , locus coeruleus -LRB- LC -- 4 slices per animal on average -RRB- , M1/M2 -LRB- 25 slices per animal on average -RRB- and S1 -LRB- 20 slices per animal on average -RRB-	42207
FG	42207
neurons	42218
the propriospinal and selected supraspinal regions , i.e. , MdV/MdD -LRB- 5 slices per animal on average -RRB- , PnO / PnC -LRB- 7 slices per animal on average -RRB- , Ra -LRB- including the raphe pallidus , raphe obscurus , raphe magnus -- 20 slices per animal on average -RRB- , SpVe -LRB- 7 slices per animal on average -RRB- , LVe -LRB- 6 slices per animal on average -RRB- , locus coeruleus -LRB- LC -- 4 slices per animal on average -RRB- , M1/M2 -LRB- 25 slices per animal on average -RRB- and S1 -LRB- 20 slices per animal on average -RRB-	42229
the propriospinal	42229
supraspinal regions	42260
MdV/MdD -LRB- 5 slices per animal on average -RRB- , PnO / PnC -LRB- 7 slices per animal on average -RRB- , Ra -LRB- including the raphe pallidus , raphe obscurus , raphe magnus -- 20 slices per animal on average -RRB- , SpVe -LRB- 7 slices per animal on average -RRB- , LVe -LRB- 6 slices per animal on average -RRB- , locus coeruleus -LRB- LC -- 4 slices per animal on average -RRB- , M1/M2 -LRB- 25 slices per animal on average -RRB- and S1 -LRB- 20 slices per animal on average -RRB-	42287
MdV/MdD -LRB- 5 slices per animal on average -RRB- , PnO / PnC -LRB- 7 slices per animal on average -RRB- , Ra -LRB- including the raphe pallidus , raphe obscurus , raphe magnus -- 20 slices per animal on average -RRB-	42287
MdV/MdD -LRB- 5 slices per animal on average -RRB-	42287
MdV/MdD	42287
5 slices per animal on average	42296
5 slices	42296
animal	42309
average	42319
PnO / PnC -LRB- 7 slices per animal on average -RRB-	42329
PnO / PnC	42329
PnO	42329
PnC	42334
7 slices per animal on average	42339
7 slices	42339
animal	42352
average	42362
Ra -LRB- including the raphe pallidus , raphe obscurus , raphe magnus -- 20 slices per animal on average -RRB-	42372
Ra	42372
the raphe pallidus , raphe obscurus , raphe magnus -- 20 slices per animal on average	42386
the raphe pallidus	42386
raphe obscurus , raphe magnus -- 20 slices per animal on average	42406
raphe obscurus , raphe magnus	42406
raphe obscurus	42406
raphe magnus	42422
20 slices per animal on average	42435
20 slices	42435
animal on average	42449
animal	42449
average	42459
SpVe -LRB- 7 slices per animal on average -RRB- , LVe -LRB- 6 slices per animal on average -RRB- , locus coeruleus -LRB- LC -- 4 slices per animal on average -RRB- , M1/M2 -LRB- 25 slices per animal on average -RRB- and S1 -LRB- 20 slices per animal on average -RRB-	42469
SpVe -LRB- 7 slices per animal on average -RRB-	42469
SpVe	42469
7 slices per animal on average	42475
7 slices	42475
animal	42488
average	42498
LVe -LRB- 6 slices per animal on average -RRB-	42508
LVe	42508
6 slices per animal on average	42513
6 slices	42513
animal	42526
average	42536
locus coeruleus -LRB- LC -- 4 slices per animal on average -RRB-	42546
locus coeruleus	42546
LC	42563
4 slices per animal on average	42566
4 slices	42566
animal	42579
average	42589
M1/M2 -LRB- 25 slices per animal on average -RRB-	42599
M1/M2	42599
25 slices per animal on average	42606
25 slices	42606
animal	42620
average	42630
S1 -LRB- 20 slices per animal on average -RRB-	42643
S1	42643
20 slices per animal on average	42647
20 slices	42647
animal	42661
average	42671
a blinded observer -LRB- Iannotti et al. , 2004 ; Xu et al. , 1995 -RRB-	42707
a blinded observer	42707
Iannotti	42727
et al. , 2004 ; Xu et al. , 1995	42736
et al.	42736
2004 ; Xu et al.	42744
2004	42744
Xu et al.	42750
Xu	42750
et al.	42753
1995	42761
Axons from these nuclei	42768
Axons	42768
these nuclei	42779
project to the thoracolumbar spinal cord and play important roles in locomotor function	42792
project	42792
the thoracolumbar spinal cord	42803
important roles	42842
locomotor function	42861
Holstege and Kuypers , 1987 ; Iannotti et al. , 2004 ; Kim et al. , 2002	42881
Holstege and Kuypers	42881
Holstege	42881
Kuypers	42894
1987 ; Iannotti et al.	42903
1987	42903
Iannotti et al.	42909
Iannotti	42909
et al.	42918
2004 ; Kim et al. , 2002	42926
2004	42926
Kim et al. , 2002	42932
Kim	42932
et al. , 2002	42936
et al.	42936
2002	42944
The location and number of FG-stained cellular bodies	42951
The location and number	42951
FG-stained cellular bodies	42978
each section using an overlaid grid and a stereotaxic atlas -LRB- Paxinos and Watson , 1998 -RRB-	43026
each section	43026
an overlaid grid and a stereotaxic atlas -LRB- Paxinos and Watson , 1998 -RRB-	43045
an overlaid grid	43045
a stereotaxic atlas -LRB- Paxinos and Watson , 1998 -RRB-	43066
a stereotaxic atlas	43066
Paxinos and Watson , 1998	43087
Paxinos	43087
Watson , 1998	43099
Watson	43099
1998	43107
4.9.2	43115
Spinal tissue sparing and GAP-43 optical densitometry Images of diaminobenzidine-stained spinal cord sections -LRB- 20 × -RRB-	43122
Spinal tissue sparing and GAP-43 optical densitometry Images	43122
diaminobenzidine-stained spinal cord sections -LRB- 20 × -RRB-	43186
diaminobenzidine-stained spinal cord sections	43186
20 ×	43233
a Nikon Microscope Optiphot-2 -LRB- Japan -RRB- coupled to a CMOS camera -LRB- 518 CU , Micrometrics -RRB- and analyzed with Image J Software 1.42 q. Subsequently , digital RGB -LRB- 24-bit -RRB- images with resolution of 254 ×	43255
a Nikon Microscope Optiphot-2	43255
Japan	43286
a CMOS camera -LRB- 518 CU , Micrometrics -RRB-	43304
a CMOS camera	43304
518 CU , Micrometrics	43319
518 CU	43319
Micrometrics	43327
Image J Software 1.42 q. Subsequently , digital RGB	43359
images	43418
resolution of 254 ×	43430
resolution	43430
254 ×	43444
254 DPI	43448
grayscale -LRB- 8-bit -RRB-	43474
grayscale	43474
8-bit	43485
unequal illumination -LRB- shading correction -RRB-	43510
correction	43540
All lightning conditions and magnifications	43553
spinal tissue sparing	43629
pictures of GFAPimmunostained spinal cord sections	43652
pictures	43652
GFAPimmunostained spinal cord sections	43664
the lesion-part in the center	43722
the lesion-part	43722
the center	43741
Samples with no continuity between rostral and caudal stumps	43753
Samples	43753
no continuity between rostral and caudal stumps	43766
no continuity	43766
rostral and caudal stumps	43788
this analysis	43834
standardized background corrections	43855
black-and-white 8-bit images	43892
tissue area fractions	43942
each section	43976
not all sections of the whole spinal	43996
not all sections	43996
the whole spinal	44016
analysis , volume and total area values of spinal cord tissue sparing	44051
analysis , volume and total area values	44051
spinal cord tissue sparing	44093
average	44146
5 images	44155
each rat	44183
a mean of spared tissue	44196
a mean	44196
spared tissue	44206
experimental group -LRB- 6 animals each group -RRB- -LRB- adapted from Kubasak et al. , 2008 -RRB-	44239
experimental group -LRB- 6 animals each group -RRB-	44239
experimental group	44239
6 animals each group	44259
6 animals	44259
each group	44269
Kubasak	44295
et al. , 2008	44303
et al.	44303
2008	44311
Images of GAP-43 immunohistochemistry	44318
Images	44318
GAP-43 immunohistochemistry	44328
the injured part of the spinal cord	44380
the injured part	44380
the spinal cord	44400
standardized background corrections	44423
a mask of each spinal cord section image	44460
a mask	44460
each spinal cord section image	44470
an auto-threshold tool	44519
Image J	44547
vacuolization	44571
tissue integrity	44601
optical densities -LRB- OD -RRB- of the images	44631
optical densities -LRB- OD -RRB-	44631
optical densities	44631
OD	44650
the images	44657
whole injury regions	44687
the area of interest , i.e. , the mask itself	44715
the area of interest , i.e. ,	44715
the area of interest	44715
the area	44715
interest	44727
the mask itself	44743
the mask	44743
OD was calculated using the following formula : OD = − log -LSB- -LRB- INT -LRB- x , y -RRB- - BL -RRB- -RSB-	44760
OD	44760
the following formula : OD = − log -LSB- -LRB- INT -LRB- x , y -RRB- - BL -RRB-	44784
the following formula	44784
OD = − log -LSB- -LRB- INT -LRB- x , y -RRB- - BL -RRB-	44807
OD =	44807
− log -LSB- -LRB- INT -LRB- x , y -RRB- - BL -RRB-	44812
− log -LSB-	44812
INT -LRB- x , y -RRB- - BL	44818
INT -LRB- x , y -RRB-	44818
INT	44818
x , y	44822
x	44822
y	44824
BL	44827
INC-BL	44833
`` OD ''	44849
the optical density ; `` INT -LRB- x , y -RRB-	44857
the optical density	44857
INT -LRB- x , y -RRB-	44879
INT	44879
x , y	44884
x	44884
y	44886
intensity	44893
the intensity at pixel -LRB- x , y -RRB-	44906
the intensity	44906
pixel -LRB- x , y -RRB-	44923
pixel	44923
x , y	44930
x	44930
y	44932
`` BL '' or black	44936
`` BL ''	44936
black	44944
the intensity generated when no light goes through the material	44953
the intensity	44953
no light	44982
the material	45004
INC	45022
the intensity of the incidental light	45030
the intensity	45030
the incidental light	45047
6	45076
16 images were analyzed from each rat and 6 animals	45078
16 images	45078
each rat and 6 animals	45107
each rat	45107
6 animals	45120
group	45148
4.9.3	45156
Axon profile quantification 5-HT and CGRP fiber populations	45163
Axon profile quantification 5-HT	45163
CGRP fiber populations	45200
a Nikon Microscope Optiphot-2 -LRB- Japan -RRB-	45250
a Nikon Microscope Optiphot-2	45250
Japan	45281
a green excitation filter for the Alexa 555 signal -LRB- G-2A , Excitation -- 510/560 -RRB-	45293
a green excitation filter	45293
the Alexa 555 signal -LRB- G-2A , Excitation -- 510/560 -RRB-	45323
the Alexa 555 signal	45323
G-2A , Excitation -- 510/560	45345
G-2A	45345
Excitation -- 510/560	45351
Excitation	45351
510/560	45363
Double-labeling with GFAP antibody	45373
Double-labeling	45373
GFAP antibody	45394
the fibrous scar borders	45430
the signal for Alexa 488	45459
the signal	45459
Alexa 488	45474
a blue excitation filter -LRB- B-2A , Excitation -- 450/490 -RRB-	45503
a blue excitation filter	45503
B-2A , Excitation -- 450/490	45529
B-2A	45529
Excitation -- 450/490	45535
Excitation	45535
450/490	45547
Pictures with resolution of 254 × 254 DPI ,	45557
Pictures	45557
resolution of 254 ×	45571
resolution	45571
254 ×	45585
254 DPI	45589
magnification of 200 ×	45612
magnification	45612
200 ×	45629
a CMOS camera -LRB- 518 CU , Micrometrics -RRB-	45640
a CMOS camera	45640
518 CU , Micrometrics	45655
518 CU	45655
Micrometrics	45663
Image J Software	45695
1.42 q	45712
The total area occupied by 5-HT or CGRP axons	45719
The total area	45719
5-HT or CGRP axons	45746
the rostral , lesion and caudal regions	45794
the width of the tissue sections	45845
the width	45845
the tissue sections	45858
5-HT fibers	45889
pictures	45902
the rostral stump -LRB- in the region with abundant visible astrocytes -RRB- , the central part of the lesion -LRB- approximately -RRB-	45925
the rostral stump -LRB- in the region with abundant visible astrocytes -RRB-	45925
the rostral stump	45925
the region with abundant visible astrocytes	45947
the region	45947
abundant visible astrocytes	45963
the central part of the lesion -LRB- approximately -RRB-	45993
the central part	45993
the lesion -LRB- approximately -RRB-	46013
the lesion	46013
the scar border of the caudal stump	46049
the scar border	46049
the caudal stump	46068
images of CGRP fibers	46099
images	46099
CGRP fibers	46109
the caudal stump -LRB- in the region with abundant visible astrocytes -RRB-	46135
the caudal stump	46135
the region with abundant visible astrocytes	46156
the region	46156
abundant visible astrocytes	46172
the central part of the lesion -LRB- approximately -RRB-	46205
the central part	46205
the lesion -LRB- approximately -RRB-	46225
the lesion	46225
the scar border of the rostral stump	46261
the scar border	46261
the rostral stump	46280
All images	46299
average , 19 pictures per spinal cord region in each animal , 6 animals per group	46314
average	46314
19 pictures per spinal cord region in each animal	46323
19 pictures	46323
spinal cord region in each animal	46339
spinal cord region	46339
each animal	46361
6 animals per group	46374
6 animals	46374
group	46388
binary -LRB- black and white -RRB-	46412
binary	46412
black and white	46420
a constant threshold value	46441
the total percentage area -LRB- % -RRB-	46488
the total percentage area	46488
%	46515
axon fibers	46530
4.10	46544
Statistical analysis Data	46550
means	46594
SEM	46600
field	46610
locomotor scores	46616
groups using analysis of variance -LRB- ANOVA -RRB- with time as the repeated measure	46655
groups	46655
analysis of variance -LRB- ANOVA -RRB-	46668
analysis	46668
variance -LRB- ANOVA -RRB-	46680
variance	46680
ANOVA	46690
time as the repeated measure	46702
time	46702
the repeated measure	46710
there	46737
statistically significant F values -LRB- p ≤ 0.05 -RRB-	46748
statistically significant F values	46748
p ≤ 0.05	46784
p	46784
≤ 0.05	46785
Bonferroni 's post hoc tests	46793
Bonferroni 's	46793
OLP transplantation	46849
the corresponding RLP group	46874
assessment of spinal tissue sparing and regional optical densitometry	46913
assessment	46913
spinal tissue sparing and regional optical densitometry	46927
spinal tissue sparing	46927
regional optical densitometry	46953
all groups	46984
one-way ANOVA	47015
Bonferroni 's post hoc test	47041
Bonferroni 's	47041
The Kruskal -- Wallis test was used for axon profile data -LRB- 5-HT or CGRP -RRB- .	47069
The Kruskal	47069
Wallis test	47081
axon profile data -LRB- 5-HT or CGRP -RRB-	47106
axon profile data	47106
5-HT or CGRP	47125
5-HT	47125
CGRP	47133
Values	47140
SPSS 11.5 -LRB- Statistical Package for the Social Sciences , Inc. , USA -RRB-	47159
SPSS 11.5	47159
Statistical Package for the Social Sciences	47170
Statistical Package	47170
the Social Sciences	47194
Inc. , USA	47215
Inc.	47215
USA	47221
Acknowledgments The authors	47228
Acknowledgments	47228
The authors	47244
Lorena F. Orlandini for animal care , Henrique B. Biehl and Carlos E. L. Santos	47276
Lorena F. Orlandini	47276
animal care , Henrique B. Biehl and Carlos E. L. Santos	47300
animal care	47300
Henrique B. Biehl	47313
Carlos E. L. Santos	47335
their assistance with confocal microscopy -LRB- Centro de Microscopia Eletrônica da UFRGS -RRB-	47359
their assistance with confocal microscopy	47359
their assistance	47359
confocal microscopy	47381
Centro de Microscopia Eletrônica da UFRGS	47402
Technical assistance	47446
Silvia Barbosa and Antônio Severino	47483
Silvia Barbosa	47483
Antônio Severino	47502
We	47520
Ana Paula Horn and Lauren Valentim for their helpful information in immunofluorescence	47534
Ana Paula Horn and Lauren Valentim	47534
their helpful information in immunofluorescence	47573
their helpful information	47573
immunofluorescence	47602
This study	47622
grants from CNPq and CAPES	47650
grants	47650
CNPq and CAPES	47662
There	47678
no conflict of interests	47688
no conflict	47688
interests	47703
R E F E R E N C E S Au , E. , Roskams , A.J. , 2003 .	47715
R E F E R E N C E S Au	47715
E. , Roskams , A.J. , 2003	47739
E. , Roskams , A.J. ,	47739
2003	47758
Olfactory ensheathing cells of the lamina propria in vivo and in vitro .	47764
Olfactory ensheathing cells	47764
the lamina propria in vivo and in vitro	47795
the lamina propria	47795
vivo	47817
Glia 41 , 224 -- 236 .	47836
Glia 41	47836
224 -- 236	47845
Barakat , D.J. , Gaglani , S.M. , Neravetla , S.R. , Sanchez , A.R. , Andrade , C.M. , Pressman , Y. , Puzis , R. , Garg , M.S. , Bunge , M.B. , Pearse , D.D. , 2005 .	47854
Barakat , D.J. , Gaglani , S.M. , Neravetla , S.R. , Sanchez , A.R. , Andrade , C.M. , Pressman , Y. , Puzis , R. , Garg , M.S. , Bunge , M.B. , Pearse , D.D.	47854
2005	47995
Survival , integration , and axon growth support of glia	48001
Survival	48001
integration	48011
axon growth support of glia	48028
axon growth support	48028
glia	48051
the chronically contused spinal cord	48074
Cell Transplant .	48112
Cell	48112
Transplant	48117
14 , 225 -- 240 .	48129
14	48129
225 -- 240	48133
Barnett , S.C. , Riddell , J.S. , 2007 .	48142
Barnett , S.C. , Riddell , J.S.	48142
2007	48172
Olfactory ensheathing cell transplantation as a strategy for spinal cord repair -- what can it achieve ?	48178
Olfactory ensheathing cell transplantation	48178
a strategy for spinal cord repair -- what can it achieve ?	48224
a strategy	48224
spinal cord repair -- what can it achieve ?	48239
spinal cord repair	48239
it	48267
Nat .	48279
Clin	48284
Pract .	48290
Neurol	48297
3 , 152 -- 161 .	48305
3	48305
152 -- 161	48308
Basso , D.M. , Beattie , M.S. , Bresnahan , J.C. , 1996 .	48317
Basso , D.M. , Beattie , M.S. , Bresnahan , J.C.	48317
1996	48362
histological and locomotor outcomes	48375
spinal cord contusion	48417
the Pearse , D.D. , Sanchez , A.R. , Pereira , F.C. , Andrade , C.M. , Puzis , R. , Pressman , Y. , Golden , K. , Kitay , B.M. , Blits , B. , Wood , P.M. , Bunge , M.B. , 2007	48445
the Pearse , D.D. , Sanchez , A.R. , Pereira , F.C. , Andrade , C.M. , Puzis , R. , Pressman , Y. , Golden , K. , Kitay , B.M. , Blits , B. , Wood , P.M. , Bunge , M.B.	48445
2007	48594
Transplantation of Schwann cells and/or olfactory ensheathing glia into the contused spinal cord : survival , migration , axon association , and functional recovery .	48600
Transplantation	48600
Schwann cells and/or olfactory ensheathing glia into the contused spinal cord : survival , migration , axon association , and functional recovery	48619
Schwann cells	48619
olfactory ensheathing glia into the contused spinal cord : survival , migration , axon association , and functional recovery	48640
olfactory ensheathing glia	48640
the contused spinal cord : survival , migration , axon association , and functional recovery	48672
spinal cord : survival , migration , axon association ,	48685
spinal cord	48685
survival	48698
migration	48708
axon association	48719
Glia 55 , 976 -- 1000 .	48762
Glia 55	48762
976 -- 1000	48771
Prang , P. , Müller , R. , Eljaouhari , A. , Heckmann , K. , Kunz , W. , Weber , T. , Faber , C. , Vroemen , M. , Bogdahn , U. , Weidner , N. , 2006 .	48781
Prang , P. , Müller , R. , Eljaouhari	48781
A.	48817
Heckmann , K. , Kunz , W. , Weber , T. , Faber , C. , Vroemen , M. , Bogdahn , U. , Weidner , N.	48821
2006	48906
The promotion of oriented axonal regrowth in the injured spinal cord by alginate-based anisotropic capillary hydrogels .	48912
The promotion	48912
oriented axonal regrowth	48929
the injured spinal cord	48957
alginate-based anisotropic capillary hydrogels	48984
Biomaterials 27 , 3560 -- 3569 .	49032
Biomaterials 27	49032
3560 -- 3569	49049
Raisman , G. , 2001 .	49060
Raisman , G.	49060
2001	49073
Olfactory ensheathing cells -- another miracle cure for spinal cord injury ?	49079
Olfactory ensheathing cells	49079
another miracle cure for spinal cord injury	49107
another miracle cure	49107
spinal cord injury	49132
Nat .	49152
Rev. Neurosci .	49157
2 , 369 -- 375 .	49172
2	49172
369 -- 375	49175
Raisman , G. , Li , Y. , 2007 .	49184
Raisman , G. , Li , Y.	49184
2007	49205
Repair of neural pathways by olfactory ensheathing cells .	49211
Repair	49211
neural pathways	49221
olfactory ensheathing cells	49240
Nat .	49269
Rev. Neurosci .	49274
8 , 312 -- 319 .	49289
8	49289
312 -- 319	49292
Ramer , L.M. , Ramer , M.S. , Steeves , J.D. , 2005 .	49301
Ramer , L.M. , Ramer , M.S. , Steeves , J.D.	49301
2005	49342
the stage for functional repair of spinal cord injuries : a cast of thousands	49356
the stage for functional repair of spinal cord injuries	49356
the stage	49356
functional repair of spinal cord injuries	49370
functional repair	49370
spinal cord injuries	49391
a cast of thousands	49413
a cast	49413
thousands	49423
Spinal Cord 43 , 134 -- 161 .	49434
Spinal Cord 43	49434
134 -- 161	49450
Ramer , L.M. , Richter , M.W. , Roskams , A.J. , Tetzlaff , W. , Ramer , M.S. , 2004 .	49459
Ramer , L.M. , Richter , M.W. , Roskams , A.J. , Tetzlaff , W. , Ramer , M.S.	49459
2004	49529
Peripherally-derived olfactory ensheathing cells	49535
primary afferent regeneration following dorsal root injury	49599
primary afferent regeneration	49599
dorsal root injury	49639
Glia 47 , 189 -- 206 .	49659
Glia 47	49659
189 -- 206	49668
Ramón-Cueto , A. , Avila , J. , 1998 .	49677
Ramón-Cueto	49677
A.	49690
Avila	49694
J.	49701
1998	49705
Olfactory ensheathing glia : properties and function .	49711
Olfactory ensheathing glia	49711
properties and function	49739
properties	49739
function	49754
Brain Res .	49764
Brain	49764
Res	49770
Bull .	49775
46 , 175 -- 187 .	49781
46	49781
175 -- 187	49785
Ramón-Cueto , A. , Cordero , M.I. , Santos-Benito , F.F. , Avila , J. , 2000 .	49794
Ramón-Cueto	49794
A.	49807
Cordero , M.I. , Santos-Benito , F.F. , Avila , J.	49811
2000	49858
Functional recovery of paraplegic rats and motor axon regeneration in their spinal cords by olfactory ensheathing glia .	49864
Functional recovery	49864
paraplegic rats and motor axon regeneration	49887
paraplegic rats	49887
motor axon regeneration	49907
their spinal cords	49934
olfactory ensheathing glia	49956
Neuron 25 , 425 -- 435 .	49984
Neuron 25	49984
425 -- 435	49995
Ramón-Cueto , A. , Muñoz-Quiles , C. , 2011 .	50004
Ramón-Cueto , A. , Muñoz-Quiles , C.	50004
2011	50039
Clinical application of adult olfactory bulb ensheathing glia for nervous system repair .	50045
Clinical application of adult olfactory bulb	50045
Clinical application	50045
adult olfactory bulb	50069
glia for nervous system repair	50102
glia	50102
nervous system repair	50111
Exp .	50134
Neurol	50139
229 , 181 -- 194 .	50147
229	50147
181 -- 194	50152
Ramón-Cueto , A. , Plant , G.W. , Avila , J. , Bunge , M.B. , 1998 .	50161
Ramón-Cueto , A. , Plant , G.W. , Avila , J. , Bunge , M.B.	50161
1998	50215
Long-distance axonal regeneration in the transected adult rat spinal cord	50221
Long-distance axonal regeneration	50221
the transected adult rat spinal cord	50258
olfactory ensheathing glia transplants	50310
J. Neurosci .	50350
18 , 3803 -- 3815 .	50363
18	50363
3803 -- 3815	50367
Richter , M.W. , Fletcher , P.A. , Liu , J. , Tetzlaff , W. , Roskams , A.J. , 2005 .	50378
Richter , M.W. , Fletcher , P.A. , Liu , J. , Tetzlaff , W. , Roskams , A.J.	50378
2005	50447
Lamina propria and olfactory bulb ensheathing cells	50453
Lamina propria	50453
olfactory bulb ensheathing cells	50472
differential integration and migration	50513
differential axon sprouting in the lesioned spinal cord	50564
differential axon	50564
the lesioned spinal cord	50595
J. Neurosci .	50621
25 , 10700 -- 10711 .	50634
25	50634
10700 -- 10711	50638
Sasaki , M. , Black , J.A. , Lankford , K.L. , Tokuno , H.A. , Waxman , S.G. , Kocsis , J.D. , 2006 .	50651
Sasaki , M. , Black , J.A. , Lankford , K.L. , Tokuno , H.A. , Waxman , S.G. , Kocsis , J.D.	50651
2006	50733
Molecular reconstruction of nodes of Ranvier after remyelination by transplanted olfactory ensheathing cells in the demyelinated spinal cord .	50739
Molecular reconstruction	50739
nodes	50767
Ranvier	50776
remyelination	50790
transplanted olfactory ensheathing cells in the demyelinated spinal cord	50807
transplanted olfactory ensheathing cells	50807
the demyelinated spinal cord	50851
the	50851
spinal cord	50868
J. Neurosci .	50881
26 , 1803 -- 1812 .	50894
26	50894
1803 -- 1812	50898
Schiwy , N. , Brazda , N. , Muller , H.W. , 2009 .	50909
Schiwy , N. , Brazda , N. , Muller , H.W.	50909
2009	50947
regenerative axon growth of multiple fibre populations	50962
regenerative axon growth	50962
multiple fibre populations	50990
traumatic spinal cord injury following scar-suppressing treatment	51020
traumatic spinal cord injury	51020
scar-suppressing treatment	51059
Eur	51087
J. Neurosci .	51092
30 , 1544 -- 1553 .	51105
30	51105
1544 -- 1553	51109
Sternberger , L.A. , 1979 .	51120
Sternberger , L.A.	51120
1979	51139
Immunocytochemistry , second ed .	51145
Immunocytochemistry	51145
second ed	51166
John Wiley & Sons , New York .	51177
John Wiley & Sons	51177
New York	51196
Steward , O. , Sharp , K. , Selvan , G. , Hadden , A. , Hofstadter , M. , Au , E. , Roskams , J. , 2006 .	51206
Steward , O. , Sharp , K. , Selvan , G. , Hadden , A. , Hofstadter , M. , Au , E. , Roskams , J.	51206
2006	51291
A re-assessment of the consequences of delayed transplantation of olfactory lamina propria following complete spinal cord transection in rats .	51297
A re-assessment	51297
the consequences of delayed transplantation	51316
the consequences	51316
delayed transplantation	51336
olfactory lamina propria	51363
complete spinal cord transection in rats	51398
complete spinal cord transection	51398
rats	51434
Exp .	51440
Neurol	51445
198 , 483 -- 499 .	51453
198	51453
483 -- 499	51458
Takami , T. , Oudega , M. , Bates , M.L. , Wood , P.M. , Kleitman , N. , Bunge , M.B. , 2002a .	51467
Takami , T. , Oudega , M. , Bates , M.L. , Wood , P.M. , Kleitman , N. , Bunge , M.B.	51467
2002a	51543
Schwann cell but not olfactory ensheathing glia transplants	51550
Schwann cell	51550
Schwann	51550
cell	51558
olfactory ensheathing glia transplants	51571
hindlimb locomotor performance in the moderately contused adult rat thoracic spinal cord	51618
hindlimb locomotor performance	51618
the moderately contused adult rat thoracic spinal cord	51652
adult rat	51676
J. Neurosci .	51708
22 , 6670 -- 6681 .	51721
22	51721
6670 -- 6681	51725
Takami , T. , Oudega , M. , Bethea , J.R. , Wood , P.M. , Kleitman , N. , Bunge , M.B. , 2002b .	51736
Takami , T. , Oudega , M. , Bethea , J.R. , Wood , P.M. , Kleitman , N. , Bunge , M.B.	51736
2002b	51813
Methylprednisolone and interleukin-10	51820
gray matter damage in the contused Fischer rat thoracic spinal cord but do not improve functional outcome	51865
gray matter damage	51865
the contused Fischer rat thoracic spinal cord but do not improve functional outcome	51887
Fischer rat	51900
thoracic spinal cord	51912
J. Neurotrauma 19 , 653 -- 666 .	51972
J. Neurotrauma 19 , 653	51972
666	51995
Tetzlaff , W. , Okon , E.B. , Karimi-Abdolrezaee , S. , Hill , C.E. , Sparling , J.S. , Plemel , J.R. , Plunet , W.T. , Tsai , E.C. , Baptiste , D. , Smithson , L.J. , Kawaja , M.D. , Fehlings , M.G. , Kwon , B.K. , 2011 .	52000
Tetzlaff , W. , Okon , E.B. , Karimi-Abdolrezaee , S. , Hill , C.E. , Sparling , J.S. , Plemel , J.R. , Plunet , W.T. , Tsai , E.C. , Baptiste , D. , Smithson , L.J. , Kawaja , M.D. , Fehlings , M.G. , Kwon , B.K.	52000
2011	52190
A systematic review of cellular transplantation therapies for spinal cord injury .	52196
A systematic review	52196
cellular transplantation therapies	52219
spinal cord injury	52258
J. Neurotrauma 28 , 1611 -- 1682 .	52278
J. Neurotrauma 28 , 1611	52278
1682	52302
van den Berg , M.E. , Castellote , J.M. , de Pedro-Cuesta , J. , Mahillo-Fernandez , I. , 2010 .	52308
van den	52308
Berg , M.E. , Castellote , J.M. , de Pedro-Cuesta , J. , Mahillo-Fernandez , I. , 2010	52316
Berg	52316
M.E.	52322
Castellote	52328
J.M.	52340
de Pedro-Cuesta	52346
J.	52363
Mahillo-Fernandez	52367
I.	52386
2010	52390
Survival after spinal cord injury : a systematic review .	52396
Survival after spinal cord injury	52396
Survival	52396
spinal cord injury	52411
a systematic review	52431
J. Neurotrauma 27 , 1517 -- 1528 .	52452
J. Neurotrauma 27 , 1517	52452
1528	52476
Vavrek , R. , Pearse , D.D. , Fouad , K. , 2007 .	52482
Vavrek , R. , Pearse , D.D. , Fouad , K.	52482
2007	52519
Neuronal populations capable of regeneration following a combined treatment in rats with spinal cord transection .	52525
Neuronal populations	52525
regeneration following a combined treatment in rats with spinal cord transection	52557
regeneration	52557
a combined treatment in rats with spinal cord transection	52580
a combined treatment	52580
rats with spinal cord transection	52604
rats	52604
spinal cord transection	52614
J. Neurotrauma 24 , 1667 -- 1673 .	52639
J. Neurotrauma 24 , 1667	52639
1673	52663
Williams , S.K. , Franklin , R.J. , Barnett , S.C. , 2004 .	52669
Williams , S.K. , Franklin , R.J. , Barnett , S.C.	52669
2004	52716
Response of olfactory ensheathing cells to the degeneration and regeneration of the peripheral olfactory system and the involvement of the neuregulins .	52722
Response	52722
olfactory ensheathing cells	52734
the degeneration and regeneration of the peripheral olfactory system and the involvement	52765
the degeneration and regeneration	52765
the peripheral olfactory system and the involvement	52802
the peripheral olfactory system	52802
the involvement	52838
the neuregulins	52857
J. Comp .	52874
Neurol	52883
470 , 50 -- 62 .	52891
470	52891
50 -- 62	52896
Xu , X.M. , Guenard , V. , Kleitman , N. , Bunge , M.B. , 1995 .	52903
Xu , X.M. , Guenard , V. , Kleitman , N. , Bunge , M.B.	52903
1995	52953
Axonal regeneration into Schwann cell-seeded guidance channels	52959
Axonal regeneration	52959
Schwann cell-seeded guidance channels	52984
transected adult rat spinal cord	53035
J. Comp .	53069
Neurol	53078
351 , 145 -- 160 .	53086
351	53086
145 -- 160	53091
